
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Neuropharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Curr Neuropharmacol</journal-id><journal-id journal-id-type="publisher-id">CN</journal-id><journal-title-group><journal-title>Current Neuropharmacology</journal-title></journal-title-group><issn pub-type="ppub">1570-159X</issn><issn pub-type="epub">1875-6190</issn><publisher><publisher-name>Bentham Science Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23450042</article-id><article-id pub-id-type="pmc">3468881</article-id><article-id pub-id-type="publisher-id">CN-10-272</article-id><article-id pub-id-type="doi">10.2174/157015912803217288</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer&#x02019;s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Yu-Jhen</given-names></name><xref ref-type="aff" rid="affa">a</xref><xref ref-type="aff" rid="affb">b</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Chieh-Hsin</given-names></name><xref ref-type="aff" rid="affa">a</xref><xref ref-type="aff" rid="affc">c</xref></contrib><contrib contrib-type="author"><name><surname>Lane</surname><given-names>Hsien-Yuan</given-names></name><xref ref-type="aff" rid="affa">a</xref><xref ref-type="aff" rid="affb">b</xref></contrib><contrib contrib-type="author"><name><surname>Tsai</surname><given-names>Guochuan E</given-names></name><xref ref-type="aff" rid="affd">d</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="affa"><label>a</label>Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan</aff><aff id="affb"><label>b</label>Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan</aff><aff id="affc"><label>c</label>Department of Psychiatry, Chang Gung Memorial Hospital &#x02013; Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan</aff><aff id="affd"><label>d</label>Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, California, and Los Angeles Biomedical Research Institute</aff><author-notes><corresp id="cor1"><label>*</label>Address correspondence to this author at the Department of Psychiatry, Harbor-UCLA Medical Center, 1000 W Carson St, Torrance, CA 90502; Tel: 310-781-1401; Fax: 310-781-1093; E-mail: <email xlink:href="etsai@labiomed.org">etsai@labiomed.org</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2012</year></pub-date><pub-date pub-type="epub"><month>9</month><year>2012</year></pub-date><volume>10</volume><issue>3</issue><fpage>272</fpage><lpage>285</lpage><history><date date-type="received"><day>2</day><month>2</month><year>2012</year></date><date date-type="rev-recd"><day>4</day><month>6</month><year>2012</year></date><date date-type="accepted"><day>9</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9;2012 Bentham Science Publishers</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.5/">http://creativecommons.org/licenses/by/2.5/</uri>), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Dementia has become an all-important disease because the population is aging rapidly and the cost of health care associated with dementia is ever increasing. In addition to cognitive function impairment, associated behavioral and psychological symptoms of dementia (BPSD) worsen patient&#x02019;s quality of life and increase caregiver&#x02019;s burden. Alzheimer&#x02019;s disease is the most common type of dementia and both behavioral disturbance and cognitive impairment of Alzheimer&#x02019;s disease are thought to be associated with the N-methyl-D-aspartate (NMDA) dysfunction as increasing evidence of dysfunctional glutamatergic neurotransmission had been reported in behavioral changes and cognitive decline in Alzheimer&#x02019;s disease. We review the literature regarding dementia (especially Alzheimer&#x02019;s disease), BPSD and relevant findings on glutamatergic and NMDA neurotransmission, including the effects of memantine, a NMDA receptor antagonist, and NMDA-enhancing agents, such as D-serine and D-cycloserine. Literatures suggest that behavioral disturbance and cognitive impairment of Alzheimer&#x02019;s disease may be associated with excitatory neurotoxic effects which result in impairment of neuronal plasticity and degenerative processes. Memantine shows benefits in improving cognition, function, agitation/aggression and delusion in Alzheimer&#x02019;s disease. On the other hand, some NMDA modulators which enhance NMDA function through the co-agonist binding site can also improve cognitive function and psychotic symptoms. We propose that modulating NMDA neurotransmission is effective in treating behavioral and psychological symptoms of Alzheimer&#x02019;s disease. Prospective study using NMDA enhancers in patients with Alzheimer&#x02019;s disease and associated behavioral disturbance is needed to verify this hypothesis. </p></abstract><kwd-group><title>Keywords</title><kwd>D-serine</kwd><kwd>glycine transporter</kwd><kwd>memantine</kwd><kwd>sarcosine. </kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>Dementia is a devastating mental disorder with high morbidity and mortality [<xref ref-type="bibr" rid="R1">1</xref>]. The prevalence of dementia doubles every 5 years in the elderly people aged between 65 to 85 years old [<xref ref-type="bibr" rid="R2">2</xref>]. It affects 1.5% of the population at the age of 65 and &#x0003e;20% by the age of 85 [<xref ref-type="bibr" rid="R3">3</xref>]. The overall age structure also favors an ever-increasing rate of dementia due to the extension of life span. In 2005, up to 24.3 million people were suffering from dementia worldwide [<xref ref-type="bibr" rid="R4">4</xref>]. In 2010, it was estimated that 35 million people in the world had dementia [<xref ref-type="bibr" rid="R5">5</xref>]. The population of dementia is expected to reach 65 million by 2030 and 113 million by 2050 [<xref ref-type="bibr" rid="R5">5</xref>]. The high prevalence and incidence of dementia in the elderly are noteworthy health and social problems. Nowadays, the underlying total cost of health care for dementia patients is as high as $385 billion [<xref ref-type="bibr" rid="R1">1</xref>] , which representing a heavy care burden to families of such patients and whole society.</p><sec><title>NMDA Neurotransmission Plays a Vital Role in Cognitive Function</title><p>Dementia is a disorder of memory and cognitive impairment. The most common type of dementia is Alzheimer&#x02019;s disease (AD), which is a neurodegenerative disorder. Many neurotransmitter systems are involved in the pathophysiology of Alzheimer&#x02019;s disease and a critical one of them is N-Methyl-D-aspartate receptor (NMDAR)-mediated neurotransmission [<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R7"> 7</xref>]. </p><p>The NMDA receptor (NMDAR) is a tetramer composed of two NR1 subunits and two NR2 subunits or less commonly, two NR3 subunits. NMDAR activation leads to Ca<sup>2+</sup> influx and triggers downstream signal transduction. Once NMDAR is activated, Ca<sup>2+</sup> enters the cell. Then, calmodulin-dependent kinase (CaMK) and cAMP response element-binding (CREB) protein are phosphorylated and trigger gene transcription needed for long term potentiation (LTP) formation. This is the molecular basis of neural plasticity and memory formation [<xref ref-type="bibr" rid="R8">8</xref>]. NMDA neurotransmission also activates protein kinase-A (PKA) and Ras pathway [<xref ref-type="bibr" rid="R9">9</xref>]. The former can in turn modulate NMDAR function [<xref ref-type="bibr" rid="R9">9</xref>] and the latter further induces mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) and phosphoinositide 3 (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways, which are important for neural survival [<xref ref-type="bibr" rid="R10">10</xref>].</p><p>Activation of NMDAR requires occupation of both glutamate and &#x0201c;glycine&#x0201d; binding sites. Although it was named &#x0201c;glycine&#x0201d; binding site, D-serine is also endogenous full agonist that is more or equally potent than glycine. The glutamate-binding site is on the NR2 subunit, and the glycine-binding site is on the NR1 subunit [<xref ref-type="bibr" rid="R11">11</xref>]. Each NR subunit has its own isoforms or subtypes. The NR1 subunit has 8 isoforms by alternative RNA splicing, and there are 4 subtypes of NR2 subunit and 2 subtypes of NR3 subunit from different encoding genes. Different compositions of NMDARs have different anatomical distributions, developmental profile and functional properties [<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13"> 13</xref>]. The subunit composition and number of NMDARs in the synaptic surface are regulated by NMDAR trafficking, which is a dynamic process involving receptor retrieval, endocytosis, and lateral diffusion [<xref ref-type="bibr" rid="R14">14</xref>]. NMDAR trafficking can be regulated by synaptic activity. For example, LTP leads to expression of synaptic NMDAR [<xref ref-type="bibr" rid="R15">15</xref>] and long-term depression (LTD) is associated with NMDAR endocytosis [<xref ref-type="bibr" rid="R16">16</xref>]. Besides, glycogen synthase kinase 3 (GSK-3), a key kinase of signal transduction involved in neuroprotection, also regulates NMDAR trafficking. Inhibition of GSK-3 activity increases NMDAR internalization and reduces NMDAR-mediated current [<xref ref-type="bibr" rid="R17">17</xref>].</p><p>The dysregulation of NMDAR trafficking is associated with neuropsychiatric disorders, such as AD [<xref ref-type="bibr" rid="R14">14</xref>]. It is consistent with the critical role NMDA neurotransmission plays in the memory formation, learning and neuronal plasticity [<xref ref-type="bibr" rid="R18">18</xref>-<xref ref-type="bibr" rid="R20">20</xref>]. Increasing NMDAR function by over-expression or underdegradation of NR2B subunit in hippocampus can enhance LTP and learning [<xref ref-type="bibr" rid="R21">21</xref>,<xref ref-type="bibr" rid="R22"> 22</xref>]. On the other hand, decrease of NR2B-containing receptor impairs LTP induction [<xref ref-type="bibr" rid="R20">20</xref>] and elimination of NR2B subunit function in area CA1 of hippocampus reduces neuron dendritic spine density and interferes with memory consolidation and learning [<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R24"> 24</xref>]. Specific ablation of NMDAR gene in the CA3 pyramidal cells of hippocampus in adult mice also results in deficits in their associative memory recall [<xref ref-type="bibr" rid="R25">25</xref>]. Besides, pharmacological blockade of NMDAR function leads to brain atrophy, impaired neuroplasticity, and learning disability [<xref ref-type="bibr" rid="R26">26</xref>-<xref ref-type="bibr" rid="R28">28</xref>]. </p></sec><sec><title>Bi-directional Involvement of NMDAR Function in the Pathophysiology of Alzheimer&#x02019;s Disease</title><p>Although NMDAR function is vital for memory and cognitive function, its role in the pathophysiology of AD is still not completely understood. NMDAR over-activation by glutamate leads to cell death mediated by calcium overload, which is called excitotoxicity [<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R29"> 29</xref>]. The excitotoxicity is one of the accepted neurochemical model of AD. The underlying mechanism of excitotoxicity in pathophysiology of AD may be involved with amyloid-&#x003b2; peptide (A&#x003b2;), which is the hallmark of the pathogenesis of AD [<xref ref-type="bibr" rid="R30">30</xref>]. There are mutual interactions between NMDAR and A&#x003b2;. A&#x000df; increases NMDAR activity [<xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R32"> 32</xref>], induces inward Ca<sup>2+</sup> current and neurotoxicity [<xref ref-type="bibr" rid="R33">33</xref>]. In turn, NMDAR activation stimulates A&#x003b2; production [<xref ref-type="bibr" rid="R34">34</xref>-<xref ref-type="bibr" rid="R36">36</xref>] and A&#x003b2; associated synaptic loss may be NMDA&#x02013;dependent [<xref ref-type="bibr" rid="R37">37</xref>].</p><p>On the contrary, the NMDA signaling pathways in the cerebral cortex and hippocampus are impaired in the aging brain [<xref ref-type="bibr" rid="R38">38</xref>]. Synaptic NMDA neurotransmission is crucial to neuronal survival. Synaptic NMDAR hypofunction leads to apoptosis [<xref ref-type="bibr" rid="R39">39</xref>,<xref ref-type="bibr" rid="R40"> 40</xref>]. Blockade of NMDAR function by gene deletion of NMDAR or using NMDAR antagonist increases apoptotic cell death [<xref ref-type="bibr" rid="R39">39</xref>-<xref ref-type="bibr" rid="R45">45</xref>]. For example, MK-801, an NMDAR antagonist, activates caspase-3 pathway and triggers apoptotic pathway [<xref ref-type="bibr" rid="R46">46</xref>]. These complex neuroprotective/neurotoxic effects of NMDAR relies on many underlying signaling pathways, including ERK, Akt and GSK pathways [<xref ref-type="bibr" rid="R47">47</xref>]. NMDAR antagonists lead to apoptotic neurodegeneration through impairing ERK/CREB pathway and <italic>Bcl2</italic> expression [<xref ref-type="bibr" rid="R48">48</xref>]. Decrease of Akt activity and increase of GSK activity are found after NMDAR antagonist administration. Inhibition of GSK activity can decrease caspase-3 activity and block NMDAR antagonist-induced neurotoxicity [<xref ref-type="bibr" rid="R49">49</xref>]. This NMDAR hypoactivity-induced neurodegeneration is postulated to contribute to the pathogenesis of AD [<xref ref-type="bibr" rid="R50">50</xref>,<xref ref-type="bibr" rid="R51"> 51</xref>]. </p><p>Other studies also suggest that NMDAR hypofunction is related to brain dysfunction in aging. Decreased NMDAR activity by knocking down NR2B expression in young rats leads to impairment of LTP and spatial learning, which mimics age-related deficits [<xref ref-type="bibr" rid="R52">52</xref>]. The aging brain with declining memory and cognitive function is associated with decreased NMDAR [<xref ref-type="bibr" rid="R53">53</xref>,<xref ref-type="bibr" rid="R54"> 54</xref>], change of NR subunit composition [<xref ref-type="bibr" rid="R55">55</xref>-<xref ref-type="bibr" rid="R57">57</xref>], diminished NMDAR binding activity [<xref ref-type="bibr" rid="R58">58</xref>] and attenuated NMDA-dependent LTP [<xref ref-type="bibr" rid="R59">59</xref>]. Besides, the redox site on NMDARs is in a more oxidized state in aged rats than that in young ones and this altered redox state may lead to reduced NMDR responses through Ca<sup>2+</sup>/CaMKII dependent mechanism during aging [<xref ref-type="bibr" rid="R60">60</xref>].</p><p>NMDAR hypofunction may be involved in the progression of aging brain from mild cognitive impairment to AD. Blockade of NMDAR function by NMDAR antagonist in rhesus monkey impairs visuo-spatial paired-associate learning, which represents early cognitive impairment of AD [<xref ref-type="bibr" rid="R61">61</xref>]. Individuals with AD or merely mild cognitive impairment have fewer NMDAR in the frontal cortex and hippocampus [<xref ref-type="bibr" rid="R62">62</xref>,<xref ref-type="bibr" rid="R63"> 63</xref>]. One study of genetic polymorphisms of NR2B subunit promoter in sporadic AD suggests that allele which leads to lower NR2B subunit expression is associated with AD [<xref ref-type="bibr" rid="R64">64</xref>]. In the genetic mouse model of AD, expression of surface NMDAR in neuron is decreased [<xref ref-type="bibr" rid="R65">65</xref>] and NMDAR-mediated response is impaired progressively with age [<xref ref-type="bibr" rid="R66">66</xref>,<xref ref-type="bibr" rid="R67"> 67</xref>]. In another study, NR1/NR2B receptor expression levels are reduced with increasing pathological severity in the post-mortem tissue of AD patients [<xref ref-type="bibr" rid="R68">68</xref>]. In addition to reduced number of NMDARs, disrupted glutamatergic neurotransmission [<xref ref-type="bibr" rid="R34">34</xref>], decreased CSF concentrations of excitatory amino acids [<xref ref-type="bibr" rid="R69">69</xref>], decreased serum level of D-serine [<xref ref-type="bibr" rid="R70">70</xref>] and reduced D-aspartate uptake [<xref ref-type="bibr" rid="R71">71</xref>] are also noted in AD.</p><p>Furthermore, the interactions between acetylcholine (ACh) and NMDA neurotransmission may account for the pathophysiology of AD. ACh is one of major neurotransmitter in central nervous system and is crucial for memory and cognition. The cholinergic hypothesis is one of the most acceptable mechanisms about pathophysiology of AD. Cognitive decline in aging and dementia are related to decreased cholinergic function [<xref ref-type="bibr" rid="R72">72</xref>,<xref ref-type="bibr" rid="R73"> 73</xref>]. Administration of anticholinergic drugs results in memory impairments which resemble AD [<xref ref-type="bibr" rid="R74">74</xref>]. Loss of cholinergic neurons and decreased synaptic ACh level are found in the brain of AD [<xref ref-type="bibr" rid="R75">75</xref>] and the extent of cholinergic deficits correlates with the severity of AD [<xref ref-type="bibr" rid="R76">76</xref>]. Clinically, acetylcholinesterase (AChE) inhibitors which increase synaptic ACh level by decreasing degradation of ACh are one of the treatment options in AD [<xref ref-type="bibr" rid="R77">77</xref>]. </p><p>Both upreguation and downregulartion are found in the interaction between ACh and NMDA neurotransmission. Some studies suggest that ACh can potentiate NMDAR related signaling pathways in the hippocampus [<xref ref-type="bibr" rid="R78">78</xref>,<xref ref-type="bibr" rid="R79"> 79</xref>]. Other studies indicate that ACh and nicotinic ACh receptor agonist inhibit NMDAR-mediated currents [<xref ref-type="bibr" rid="R80">80</xref>]. Besides, AChE inhibitor may exert its neuroprotective effect by decreasing glutamate excitotocity. AChE inhibitor can reduce expression of NR1 subunit on cell surface, decrease glutamate-mediated Ca<sup>2+</sup> influx [<xref ref-type="bibr" rid="R81">81</xref>] and reduce NMDAR mediated excitatory current through nicotinic receptor mediated Ca<sup>2+</sup>- dependent mechanism and activation of ERK pathway [<xref ref-type="bibr" rid="R82">82</xref>]. The modulation of AChE inhibitor on NMDA neurotransmission is impaired in amyloid precursor protein (APP) transgenic mouse model of AD [<xref ref-type="bibr" rid="R82">82</xref>].</p><p>As mentioned before, A&#x003b2; deposition plays an important role in pathophysiology of AD. Although some evidences show that the underlying mechanism of glutamate excitotocity in AD may be related to A&#x003b2; deposition, the opposing findings about the modulation between NMDA neurotransmission and A&#x003b2; formation are found. NMDAR activation can reduce A&#x003b2; production by enhancing non-amyloidogenic processing of APP [<xref ref-type="bibr" rid="R83">83</xref>,<xref ref-type="bibr" rid="R84"> 84</xref>]. On the other hand, A&#x003b2; aggregation interferes with NMDA neurotransmission, which may lead to cognitive function impairment as A&#x003b2; impairs NMDA&#x02013;dependent LTP both <italic>in vivo</italic> and <italic>in vitro</italic> [<xref ref-type="bibr" rid="R85">85</xref>-<xref ref-type="bibr" rid="R87">87</xref>]. A&#x003b2; also suppresses NMDAR-dependent synaptic function [<xref ref-type="bibr" rid="R88">88</xref>] by decreasing NR2 tyrosine phosphorylation, increasing endocytosis of NMDAR [<xref ref-type="bibr" rid="R65">65</xref>,<xref ref-type="bibr" rid="R89"> 89</xref>,<xref ref-type="bibr" rid="R90"> 90</xref>] and interfering with signal transduction of NMDAR, including the Ca<sup>2+</sup>-dependent protein phosphatase calcineurin [<xref ref-type="bibr" rid="R91">91</xref>], Ca<sup>2+</sup>/calmodulin-dependent protein kinase II [<xref ref-type="bibr" rid="R92">92</xref>], protein phosphatase [<xref ref-type="bibr" rid="R93">93</xref>], and CREB [<xref ref-type="bibr" rid="R91">91</xref>]. In addition to A&#x003b2;, apolipoprotein E4 (ApoE 4), an amyloid binding protein isoform related to the AD risk, impairs glutamatergic neurotransmission by reducing NMDAR function [<xref ref-type="bibr" rid="R94">94</xref>]. </p></sec><sec><title>Conceptualizing NMDA Modulation Treatment for Alzheimer&#x02019;s Disease</title><p>Either over or under-function of NMDA neurotransmission brings forth cognitive dysfunction or neurotoxicity. A balanced NMDAR activity is required for optimal brain function. A recent model of this &#x0201c;NMDA paradox&#x0201d; indicates that it may be related to different composition of NR subunits and receptor localization. Synaptic NMDARs, mostly assembled by NR1 and NR2A subunits, trigger the signal transduction of cell survival pathways, whereas extrasynaptic NMDARs, composed of NR1 and NR2B subunits, involve with the signal pathways of cell death [<xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11"> 11</xref>]. This complexity implies that NMDAR activity needs to be kept in an optimal range for brain function. Accordingly, normalizing NMDAR dysfunction by enhancing NR1/NR2A while avoiding excitotoxicity due to NR1/NR2B could be a better approach instead of straight NMDAR antagonism, which will impair normal physiological function like memory and cognition, desperately needed in treatment of AD, and induce side effects like apoptosis and psychosis.</p><p>In 1990's, most major pharmaceutical companies rushed to develop NMDAR antagonists as neuroprotectants for AD under the basis of &#x0201c;glutamate excitotoxicity theory&#x0201d;. However, administration of NMDAR antagonists which block the receptor completely has limited usefulness clinically due to the severe side effects such as psychosis, nausea, vomiting, memory impairment, and neuronal cell death. Several large-scale Phase III trials of NMDAR antagonists fail to show neuroprotective effects with the exception of memantine [<xref ref-type="bibr" rid="R95">95</xref>]. In fact, many NMDAR antagonists, such as ketamine, MK801 cause cognitive impairment and psychosis [<xref ref-type="bibr" rid="R96">96</xref>-<xref ref-type="bibr" rid="R100">100</xref>]. Different from other NMDAR antagonists, memantine has been demonstrated to have beneficial effects for patients with moderate&#x02013;to&#x02013;severe AD, while not mild AD [<xref ref-type="bibr" rid="R101">101</xref>]. Memantine is an uncompetitive NMDAR weak partial antagonist of low affinity, which supposedly can block the NMDAR over-activation by preventing excessive influx of calcium without affecting physiological NMDAR activity [<xref ref-type="bibr" rid="R102">102</xref>-<xref ref-type="bibr" rid="R104">104</xref>]. Consistently, therapeutically relevant plasma concentration of memantine produces only 30% NMDAR occupancy [<xref ref-type="bibr" rid="R105">105</xref>].</p><p>Other NMDA modulators have been investigated for therapeutic effect on the treatment of AD. One way to modulate NMDAR function is to enhance the function through the co-agonist binding site. Augmentation through the NMDAR-glycine binding site is preferred to avoid the excitotoxicity mediated through the glutamate binding site [<xref ref-type="bibr" rid="R106">106</xref>]. Enhancers of NMDAR-glycine binding site include full agonist (<italic>e.g.</italic> glycine, D-serine and D-alanine), partial agonist (<italic>e.g</italic>. D-cycloserine), and glycine transporter 1 (GlyT1) inhibitor (<italic>e.g.</italic> sarcosine), that blocks the reuptake of glycine [<xref ref-type="bibr" rid="R107">107</xref>]. In mouse model, the learning deficits caused by NMDAR hypofunction in mice with point mutations in NMDAR glycine binding site can be rescued by administration of D-serine [<xref ref-type="bibr" rid="R108">108</xref>,<xref ref-type="bibr" rid="R109"> 109</xref>]. Supporting neurotrophic/cognitive effects, D-cycloserine can improve cognitive functions in animal study [<xref ref-type="bibr" rid="R110">110</xref>-<xref ref-type="bibr" rid="R112">112</xref>]. The learning and memory enhancing effects of D-cycloserine are in a dose-dependent manner [<xref ref-type="bibr" rid="R110">110</xref>]. However, the cognition-enhancing effects of D-cycloserine in AD are controversial in other studies [<xref ref-type="bibr" rid="R113">113</xref>-<xref ref-type="bibr" rid="R117">117</xref>]. Another NMDAR modulator, GLYX-13, which is a monoclonal antibody-derived peptide acting as an agonist at NMDAR glycine binding site, can enhance learning and memory in both healthy young and impaired aging rats. Interestingly, the learning-improving effect is more prominent in old than in young rats [<xref ref-type="bibr" rid="R118">118</xref>,<xref ref-type="bibr" rid="R119"> 119</xref>].</p></sec><sec><title>Behavioral and Psychological Symptoms: the other Critical Therapeutic Dimension of Dementia</title><p>In addition to memory and cognitive function impairment, behavioral and psychological symptoms associated with dementia (BPSD) are main contributors to poor life quality of patients with dementia and burden to their caregivers. The concept of BPSD was developed in late 1980s and its definition was affirmed as &#x0201c;a term used to describe a heterogeneous range of psychological reactions, psychiatric symptoms, and behavior occurring in people with dementia of any etiology&#x0201d; in the International Psychogeriatric Association (IPA) consensus conference in 1996 [<xref ref-type="bibr" rid="R120">120</xref>]. Clinically, BPSD includes four domains: 1. behavior, including aggression, agitation, sleep disturbance, sexual disinhibition, etc. 2. mood, including depression, anxiety, mania, etc, 3. thought content, including delusions, illogical thoughts, etc, 4. perception, including hallucinations and misidentification [<xref ref-type="bibr" rid="R121">121</xref>-<xref ref-type="bibr" rid="R123">123</xref>]. The clinical manifestations of BPSD may vary with different types of dementia. For example, mood changes, such as anxiety, depression, emotional labiality and apathy, are more common and psychotic symptoms are fewer in vascular dementia (VaD) [<xref ref-type="bibr" rid="R124">124</xref>]. BPSD may be more severe in VaD than in AD [<xref ref-type="bibr" rid="R125">125</xref>]. Predominant symptoms of BPSD also differ at different stages of dementia. For example, depression is common in the early stage of dementia and psychotic symptoms occur more frequently with disease progression [<xref ref-type="bibr" rid="R126">126</xref>,<xref ref-type="bibr" rid="R127"> 127</xref>].</p><p>The prevalence of BPSD is very high in patients with dementia, with 64% at initial evaluation [<xref ref-type="bibr" rid="R128">128</xref>] and 90% over the whole course of illness [<xref ref-type="bibr" rid="R129">129</xref>]. The severity of BPSD is related to the severity of dementia of all types [<xref ref-type="bibr" rid="R126">126</xref>,<xref ref-type="bibr" rid="R130"> 130</xref>,<xref ref-type="bibr" rid="R131"> 131</xref>]. The development of BPSD is associated with a poorer prognosis, a more rapid rate of cognitive decline and illness progression [<xref ref-type="bibr" rid="R132">132</xref>]. Besides, BPSD is distressful to patients, care givers, and professionals [<xref ref-type="bibr" rid="R133">133</xref>]. Untreated BPSD contributes to over-medication [<xref ref-type="bibr" rid="R132">132</xref>,<xref ref-type="bibr" rid="R133"> 133</xref>], premature institutionalization [<xref ref-type="bibr" rid="R128">128</xref>,<xref ref-type="bibr" rid="R129"> 129</xref>], increased financial cost [<xref ref-type="bibr" rid="R120">120</xref>], decreased quality of life for both the caregivers and the patients [<xref ref-type="bibr" rid="R134">134</xref>,<xref ref-type="bibr" rid="R135"> 135</xref>], significant stress to caregiver [<xref ref-type="bibr" rid="R136">136</xref>], nursing staff in residential facilities [<xref ref-type="bibr" rid="R137">137</xref>], and excess disability [<xref ref-type="bibr" rid="R138">138</xref>].</p></sec><sec><title>Lack of Effective and Safe Treatment for Behavioral Symptoms in BPSD</title><p>Although BPSD is very common in dementia and contributes to poor outcome, no pharmacological therapy is particularly effective [<xref ref-type="bibr" rid="R139">139</xref>] and no medication has yet been approved by the Food and Drug Administration (FDA) for treating BPSD to date.</p><p>Antipsychotic medications have been used clinically for treating the behavioral disturbances and psychosis of dementia, but the evidence of their efficacy and safety is scanty [<xref ref-type="bibr" rid="R140">140</xref>]. Although some studies of psychotropic agents reveal positive results, most of them are open label studies, or with small sample size [<xref ref-type="bibr" rid="R141">141</xref>]. Large-scale studies have demonstrated negative findings. For example, the Clinical Antipsychotic Trials of Intervention Effectiveness&#x02014;Alzheimer&#x02019;s Disease (CATIE-AD) indicates that the response rates of olanzapine, risperidone, and quetiapine are similar to that of placebo [<xref ref-type="bibr" rid="R142">142</xref>]. Moreover, atypical antipsychotics are associated with more deterioration of cognitive function in patients with AD [<xref ref-type="bibr" rid="R143">143</xref>], suggesting that antipsychotic medication is not a effective treatment option for both cognitive symptoms and BPSD.</p><p>In 2005, FDA (USA) issued a warning that, among elderly with dementia, treatment of behavioral disorders with atypical antipsychotics is associated with a higher mortality rate. Specific causes of deaths are mostly cardiac related or infections [<xref ref-type="bibr" rid="R144">144</xref>]. The FDA also suggests that typical antipsychotics have similarly higher mortality risk. This concern is confirmed by a meta-analysis showing that haloperidol, a widely used typical antipsychotic agent, carries a relative mortality risk of 2.07 [<xref ref-type="bibr" rid="R145">145</xref>] and by another study demonstrating that mortality risks with typical antipsychotics are higher than with atypical antipsychotic agents in elderly patients [<xref ref-type="bibr" rid="R146">146</xref>]. Another meta-analysis of 17 placebo controlled trials of atypical antipsychotics for the treatment of BPSD conducted by the FDA suggests a significant increase in mortality, too [<xref ref-type="bibr" rid="R145">145</xref>]. The Cochrane Reviews find that risperidone and olanzapine are useful in reducing BPSD, but both are associated with serious adverse cerebrovascular events and extrapyramidal syndrome. Thus, the Cochrane Reviews suggest that neither risperidone nor olanzapine should be used routinely to treat BPSD [<xref ref-type="bibr" rid="R147">147</xref>]. Taken together, these findings suggest that antipsychotic agents carry substantial risk for treating the dementia patients with BPSD.</p><p>The therapeutic effects of AChE inhibitors, which are the main medications for the treatment of AD, on the treatment of BPSD are uncertain. Although clinical trials evaluating behavioral effect of AChE inhibitors showed potential treatment benefit for behavioral symptoms, some randomized controlled studies revealed negative results (Table <bold><xref ref-type="table" rid="T1">1</xref></bold>). In a meta-analysis, there was small advantage of AChE inhibitors over placebo with a modest improvement of 1.72 points on the Neuropsychiatric Inventory (NPI) and 0.03 points on the Alzheimer Disease Assessment Scale, noncognitive (ADAS-noncog) [<xref ref-type="bibr" rid="R167">167</xref>].</p><p>Anticonvulsants, such as carbamazepine and valproate, are beneficial in the treatment of behavioral disturbance of dementia in small-scale studies; however, larger studies show negative results [<xref ref-type="bibr" rid="R132">132</xref>,<xref ref-type="bibr" rid="R141"> 141</xref>,<xref ref-type="bibr" rid="R168"> 168</xref>]. Therefore, anti-convulsants are not recommended for the treatment of BPSD [<xref ref-type="bibr" rid="R169">169</xref>]. </p><p>In summary, due to the lack of effective and safe medication for treating behavioral disturbance in AD, novel therapeutic approach is desperately needed for the treatment of BPSD.</p></sec><sec><title>The Therapeutic Potential of NMDA Modulators for the Treatment of Behavioral Symptoms in Alzheimer&#x02019;s Disease</title><p>While BPSD may be an endophenotype of neurotransmitter-associated gene variation in AD [<xref ref-type="bibr" rid="R170">170</xref>], the etiology of BPSD is complex and unclear. Dysregulations in cholinergic, serotonergic, dopaminergic, noradrenergic, and &#x003b3;-aminobutyric acid (GABA) neurotransmitter systems are all involved in the neurobiology of mood, thought and behavior disturbance in patients with dementia [<xref ref-type="bibr" rid="R120">120</xref>,<xref ref-type="bibr" rid="R132"> 132</xref>,<xref ref-type="bibr" rid="R171"> 171</xref>]. Considering the complexity and diversity of pathophysiology in different types of dementia, we focus the discussion on BPSD in AD. </p><p>Briefly, decreased cholinergic function correlates with cognitive impairment and aggression in AD patients [<xref ref-type="bibr" rid="R172">172</xref>]. Deficits in cholinergic neurotransmission may also lead to behavioral disturbances such as psychosis, agitation and personality changes in AD [<xref ref-type="bibr" rid="R173">173</xref>]. Dysfunction of serotonergic system may contribute to BPSD in AD. Serotonin secretion and serotonin receptor density are decreased in AD patients [<xref ref-type="bibr" rid="R174">174</xref>]. Serotonin hypofunction may be linked to psychosis and anxiety and hyper-response of serotonin receptor may be associated with aggression in AD patients [<xref ref-type="bibr" rid="R174">174</xref>]. Genetic studies also revealed an association between serotonin neurotransmission and BPSD. Serotonin receptor 5HT2A polymorphism is associated with psychotic symptoms, such as hallucination and delusion, and aberrant motor behavior in AD [<xref ref-type="bibr" rid="R175">175</xref>]. Significant association was also found between genetic variation in the serotonin transporter gene and behavioral disturbances, such as aggression, irritability and psychosis in probable and mild AD patients [<xref ref-type="bibr" rid="R176">176</xref>-<xref ref-type="bibr" rid="R178">178</xref>].</p><p>Dopaminergic system dysfunction is related to AD patient with BPSD, especially the symptom of apathy [<xref ref-type="bibr" rid="R179">179</xref>]. A study indicates that the binding potential of dopamine receptor correlates inversely with severity of BPSD in AD [<xref ref-type="bibr" rid="R180">180</xref>]. Besides, there are correlations between dopamine associated gene polymorphism and BPSD, such as dopamine transporter gene 3' variable number tandem repeats (VNTR) and agitation, dopamine receptor 4 VNTR and mood component [<xref ref-type="bibr" rid="R178">178</xref>], and dopamine receptor 3 glycine allele and paranoid ideation [<xref ref-type="bibr" rid="R181">181</xref>].</p><p>Other neurotransmitter systems, such as norepinephrine (NE), GABA, are also related to BPSD. Loss of NE neuron with compensated increasing NE activity may lead to BPSD in AD [<xref ref-type="bibr" rid="R182">182</xref>]. Higher density of GABA receptors in the temporal cortex correlates with more severe depression in AD [<xref ref-type="bibr" rid="R183">183</xref>]. Another study suggests that plasma GABA concentration is related to depression and apathy in severe AD [<xref ref-type="bibr" rid="R184">184</xref>].</p><p>In addition, AD associated behavior disturbance may be partly due to aberrant NMDA neurotransmission. Although the definitive role of NMDA neurotransmission in BPSD still needs to be elucidated, NMDAR dysfunction is indeed involved in psychiatric and behavioral symptoms, such as agitation, depression, anxiety and psychotic symptoms. In animal models, NMDAR dysfunction is associated with agitation and aggression. NMDA neurotransmission is involved in regulating aggressive behavior in cat [<xref ref-type="bibr" rid="R185">185</xref>] and NMDAR hypofunction caused by NMDAR antagonist leads to behavior disturbance, agitation and aggression in rodent [<xref ref-type="bibr" rid="R186">186</xref>,<xref ref-type="bibr" rid="R187"> 187</xref>]. Abnormal glutamatergic neurotransmission in the frontal and cingulate area is postulated to contribute to agitation in AD [<xref ref-type="bibr" rid="R188">188</xref>]. </p><p>NMDAR dysfunction is also related to depression. Decreased expression of NR1 subunit is found in the prefrontal cortex of olfactory bulbectomized rat, which is a model of depression with anxiety [<xref ref-type="bibr" rid="R189">189</xref>]. NMDAR antagonists, such as ketamine, may have antidepressant effect [<xref ref-type="bibr" rid="R190">190</xref>,<xref ref-type="bibr" rid="R191"> 191</xref>]. One possible underlying mechanism is that NMDAR antagonists activate mTOR signaling through &#x003b1;-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), ERK and Akt pathways [<xref ref-type="bibr" rid="R190">190</xref>] and mTOR activation leads to increased spine density and synaptic activity in the prefrontal cortex of rats and produces antidepressant-like behavioral effect [<xref ref-type="bibr" rid="R190">190</xref>,<xref ref-type="bibr" rid="R191"> 191</xref>]. </p><p>NMDAR is involved in fear memory formation and extinction, which is the neural basis of anxiety disorder. NMDAR antagonists have anxiolytic effects both in rodents and humans [<xref ref-type="bibr" rid="R192">192</xref>]. Mice with reduced NMDAR-glycine affinity have less anxiety-like behaviors [<xref ref-type="bibr" rid="R193">193</xref>]. Besides, D-cycloserine, a partial agonist of NR1 subunit of NMDAR, can alleviate anxious symptoms in patients with anxiety disorder [<xref ref-type="bibr" rid="R194">194</xref>]. </p><p>Dysfunction of NMDA neurotransmission also plays a critical role in the pathophysiology of schizophrenia, which presents with mood disturbance, psychosis and cognitive decline similar to dementia [<xref ref-type="bibr" rid="R27">27</xref>]. In fact, schizophrenia was first identified as dementia praecox, a term popularized by Emil Kraepelin. Clinical characteristics of BPSD include hallucinations, delusions, disorganized speech, and disturbing behavior resembled positive symptoms of schizophrenia; social withdrawal, apathy, alogia, and avolition resembled negative symptoms in schizophrenia, and behavior, sleep, or affect problems are also frequently encountered in schizophrenic patients. In genetic studies, the linkage analyses of AD with psychosis reveal some shared linkage alleles found in schizophrenia [<xref ref-type="bibr" rid="R195">195</xref>]. Animal studies also suggest that NMDAR antagonists result in anatomical and functional alterations in the same limbic structures presented in the dementia syndrome of schizophrenia and AD. This implies that NMDAR antagonists may serve as models for behavioral studies of both schizophrenia and dementia [<xref ref-type="bibr" rid="R196">196</xref>]. Taken together, these findings suggest that a partially shared susceptibility and pathophysiology may underline the psychiatric and behavioral disturbance in both schizophrenia and AD or dementia in general. </p><p>Further analysis conducted by Maria found that a single nucleotide polymorphism (rs2153674) in the G72 (D-amino acid oxidase (DAAO) activator, DAOA) gene was associated with the occurrence of psychotic symptoms in patients with AD and this allele accounted for up to 15% of the variance in delusions severity [<xref ref-type="bibr" rid="R197">197</xref>]. This allele also has some linkage disequilibrium in schizophrenia [<xref ref-type="bibr" rid="R198">198</xref>]. DAOA is a primate-specific protein that enhances DAAO activity to degrade the potent neurotransmitter of glycine coagonist binding site in NMDAR, such as D-serine and D-alanine. Dysfunction of DAOA is associated with schizophrenia [<xref ref-type="bibr" rid="R198">198</xref>].</p><p>GSK pathway may play a key role in NMDAR dysfunction in BPSD. GSK pathway is associated with neuroprotection and mood disorder. Activated GSK pathway is involved in hyperdopamine receptor-mediated inhibition of NMDAR in the prefrontal cortex, which may contribute to the associated behavioral changes [<xref ref-type="bibr" rid="R199">199</xref>]. Consistently, suppressed GSK activity can reduce ketamine-induced psychotomimetic effects, such as locomotor hyperactivity, motor incoordination, sensorimotor impairment, and cognitive deficits [<xref ref-type="bibr" rid="R200">200</xref>]. </p><p>Clinically, NMDAR dysfunction is found in AD patients with behavioral symptoms. In a study conducted by Tsang <italic>et al</italic>., twenty-one patients with AD were divided into high anxiety and low anxiety groups by Neuropsychiatric Inventory score and their NMDA subunits were assayed. They found that affinity of the glycine coagonist site of NMDAR was higher and the density of NR2A subunit was downregulated in AD patients with high anxiety score [<xref ref-type="bibr" rid="R201">201</xref>]. Above results imply that dysfunction of NMDA neurotransmission is related to behavioral and psychological symptoms of AD.</p><p>For the treatment of behavioral symptoms, memantine is postulated to have therapeutic benefits other than its modest efficacy for cognition, but the results are controversial. Significant benefits of memantine treatment on the measurement of behavior symptoms are observed in open label studies and as add-on dopenezil treatments (see Table <bold><xref ref-type="table" rid="T2">2</xref></bold>). However, in two randomized, double-blind, placebo-controlled trials comparing treatment effect of memantine to placebo, memantine is not better than placebo in improving the behavioral outcome [<xref ref-type="bibr" rid="R201">201</xref>,<xref ref-type="bibr" rid="R204"> 204</xref>]. In another randomized, double-blind, placebo-controlled trials conducted by Fox<italic> et al</italic>., the findings are mixed. There is no significant difference between memantine and placebo in Cohen-Mansfield Agitation Inventory, but memantine has significant improvement over placebo in Neuropsychiatric Inventory [<xref ref-type="bibr" rid="R211">211</xref>]. Subsequent pooled analyses suggest that memantine is modestly effective in treatment of BPSD in domains of irritability, agitation/aggression and delusion [<xref ref-type="bibr" rid="R206">206</xref>,<xref ref-type="bibr" rid="R207"> 207</xref>,<xref ref-type="bibr" rid="R212"> 212</xref>]. However, caution needs to be taken when long-term attenuation of NMDAR function by memantine can contribute to the deterioration of mood and psychotic symptoms as other NMDAR antagonists do. </p><p>Alternatively, NMDAR enhancers may improve the cognitive, mood and psychotic symptom in AD like in schizophrenia and major depression. Previous studies revealed that NMDAR enhancing agent can alleviate psychotic symptoms of patients with schizophrenia [<xref ref-type="bibr" rid="R213">213</xref>-<xref ref-type="bibr" rid="R217">217</xref>]. In addition, NMDAR-enhancing treatment can reduce depressive symptoms [<xref ref-type="bibr" rid="R213">213</xref>,<xref ref-type="bibr" rid="R214"> 214</xref>,<xref ref-type="bibr" rid="R218"> 218</xref>] and improve cognitive function in patients with schizophrenia [<xref ref-type="bibr" rid="R213">213</xref>,<xref ref-type="bibr" rid="R214"> 214</xref>,<xref ref-type="bibr" rid="R219"> 219</xref>,<xref ref-type="bibr" rid="R220"> 220</xref>]. D-serine add-on therapy can improve positive symptoms, negative symptoms and cognitive function in treatment-refractory schizophrenia as well as 14.7% decrease of depressive symptoms in a 6-week trial [<xref ref-type="bibr" rid="R220">220</xref>]. In another 6-week trial of adjuvant glycine treatment of schizophrenia, glycine can lead to about 34% reduction in negative symptoms, 11% reduction in cognitive symptoms and small but significant improvements in depression and excitement subscales [<xref ref-type="bibr" rid="R219">219</xref>]. Sarcosine, a glycine transporter-I inhibitor which potentiates glycine's action on NMDAR glycine binding site, can result in a 17% reduction of the positive symptoms, a 14% reduction of the negative symptoms and 13% improvement in the PANSS-cognitive subscale after a 6-week add-on trial [<xref ref-type="bibr" rid="R213">213</xref>]. Recently, we also found that sarcosine can improve the symptoms of major depression with fast and high remission rate [<xref ref-type="bibr" rid="R221">221</xref>]. </p><p>Agonism of the coagonist binding site of NMDAR may
be another approach to improve NMDAR function for
treatment of behavioral symptoms of AD. In addition to
glycine, D-amino acids, especially D-serine, are the agonist
of co-agonist binding site of NMDAR. D-serine can be derived from L-serine by serine racemace (SR) in astrocyte
and be uptaked by alanine-serine-cysteine transporter (ASC-1)
to pre-synaptic neuron and degraded by DAAO. Therefore,
increase of synaptic D-serine level can be achieved by
enhancement of SR, attenuation of ASC-1 or inhibition of
DAAO [<xref ref-type="bibr" rid="R107">107</xref>]. DAAO inhibitor can also increase NMDAR
associated synaptic activity without increasing D-serine level
[<xref ref-type="bibr" rid="R222">222</xref>]. To our knowledge, there is no study conducted to
explore the therapeutic effect of NMDAR enhancers in
treatment of behavioral disturbance in AD. Due to their
beneficial effects on cognition, mood, anxiety and psychosis
in a variety of mental disorders, we predict there is a good
likelihood that NMDAR enhancers can have therapeutic
efficacy in behavioral and psychological symptoms of AD.
This approach, once confirmed, will represent a novel
treatment strategy for the behavioral disturbance in AD.</p></sec></sec></body><back><ack><title>ACKNOWLEDGEMENT</title><p>This work was supported by the National Science
Council, Taiwan (NSC-100-2627-B-039-001, NSC-101-2314-B-039-030-MY3, NSC-101-2325-B-039-009, NSC 101-2314-B-182A-073-MY2), National Health Research Institutes,
Taiwan (NHRI-EX-101-9904NI), Taiwan Department of
Health Clinical Trial and Research Center of Excellence
(DOH101-TD-B-111-004), and China Medical University
Hospital, Taiwan (DMR-99-120 and DMR-100-161).</p></ack><sec><title>CONFLICT OF INTEREST STATEMENT</title><p>Conflict statement of patents: Sarcosine is protected by
US patent 6228875, 6667297, 642035, 6974821, 7704978,
AU765603, for which GET is an inventor.</p></sec><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Thies</surname><given-names>W</given-names></name><name><surname>Bleiler</surname><given-names>L</given-names></name></person-group><article-title>Alzheimer's disease facts and figures. Alzheimer's &#x00026; dementia</article-title><source>J. Alzheimer's Ass</source><year>2011</year><volume>7</volume><issue>2</issue><fpage>208</fpage><lpage>44</lpage></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Fratiglioni</surname><given-names>L</given-names></name><name><surname>De Ronchi</surname><given-names>D</given-names></name><name><surname>Aguero-Torres</surname><given-names>H</given-names></name></person-group><article-title>Worldwide prevalence and incidence of dementia</article-title><source>Drugs Aging</source><year>1999</year><volume>15</volume><issue>5</issue><fpage>365</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">10600044</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Kildea</surname><given-names>D</given-names></name></person-group><article-title>Is senile dementia "age-related" or "ageing-related"?--evidence from meta-analysis of dementia prevalence in
the oldest old</article-title><source>Lancet</source><year>1995</year><volume>346</volume><issue>8980</issue><fpage>931</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7564727</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ferri</surname><given-names>C P</given-names></name><name><surname>Prince</surname><given-names>M</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name><name><surname>Ganguli</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>K</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Hendrie</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>Global prevalence of dementia: a Delphi consensus study</article-title><source>Lancet</source><year>2005</year><volume>366</volume><issue>9503</issue><fpage>2112</fpage><lpage>2117</lpage><pub-id pub-id-type="pmid">16360788</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Breteler</surname><given-names>M M</given-names></name><name><surname>Dekosky</surname><given-names>S T</given-names></name><name><surname>Dorenlot</surname><given-names>P</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name><name><surname>Hock</surname><given-names>C</given-names></name><name><surname>Kenigsberg</surname><given-names>P A</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name></person-group><article-title>The world of dementia beyond 2020</article-title><source>J. Am. Geriatr. Soc</source><year>2011</year><volume>59</volume><issue>5</issue><fpage>923</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21488846</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>S A</given-names></name><name><surname>Rosenberg</surname><given-names>P A</given-names></name></person-group><article-title>Excitatory amino acids as a final common pathway for neurologic disorders</article-title><source>N. Engl. J. Med</source><year>1994</year><volume>330</volume><issue>9</issue><fpage>613</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">7905600</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Farber</surname><given-names>N B</given-names></name><name><surname>Newcomer</surname><given-names>J W</given-names></name><name><surname>Olney</surname><given-names>J W</given-names></name></person-group><article-title>The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease</article-title><source>Prog. Brain Res</source><year>1998</year><volume>116</volume><fpage>421</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">9932393</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>A J</given-names></name></person-group><article-title>Molecular and cellular cognitive studies of the role of synaptic plasticity in memory</article-title><source>J. Neurobiol</source><year>2003</year><volume>54</volume><issue>1</issue><fpage>224</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">12486706</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Matynia</surname><given-names>A</given-names></name><name><surname>Kushner</surname><given-names>S A</given-names></name><name><surname>Silva</surname><given-names>A J</given-names></name></person-group><article-title>Genetic approaches to molecular and cellular cognition: a focus on LTP and learning and memory</article-title><source>Annu. Rev. Genet</source><year>2002</year><volume>36</volume><fpage>687</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">12429705</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Carew</surname><given-names>T J</given-names></name></person-group><article-title>Small G protein signaling in neuronal plasticity and memory formation: the specific role of ras family proteins</article-title><source>Neuron</source><year>2010</year><volume>68</volume><issue>3</issue><fpage>340</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">21040840</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Kalia</surname><given-names>L V</given-names></name><name><surname>Kalia</surname><given-names>S K</given-names></name><name><surname>Salter</surname><given-names>M W</given-names></name></person-group><article-title>NMDA receptors in clinical neurology: excitatory times ahead</article-title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><issue>8</issue><fpage>742</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">18635022</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Hynd</surname><given-names>M R</given-names></name><name><surname>Scott</surname><given-names>H L</given-names></name><name><surname>Dodd</surname><given-names>P R</given-names></name></person-group><article-title>Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer's disease</article-title><source>J. Neurochem</source><year>2004</year><volume>90</volume><issue>4</issue><fpage>913</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15287897</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Benarroch</surname><given-names>E E</given-names></name></person-group><article-title>NMDA receptors: recent insights and clinical correlations</article-title><source>Neurology</source><year>2011</year><volume>76</volume><issue>20</issue><fpage>1750</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21576693</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>C G</given-names></name><name><surname>Zukin</surname><given-names>R S</given-names></name></person-group><article-title>NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders</article-title><source>Nat. Rev. Neurosci</source><year>2007</year><volume>8</volume><issue>6</issue><fpage>413</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">17514195</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Grosshans</surname><given-names>D R</given-names></name><name><surname>Clayton</surname><given-names>D A</given-names></name><name><surname>Coultrap</surname><given-names>S J</given-names></name><name><surname>Browning</surname><given-names>M D</given-names></name></person-group><article-title>LTP leads to rapid surface expression of NMDA but not AMPA receptors in adult rat CA1</article-title><source>Nat. Neurosci</source><year>2002</year><volume>5</volume><issue>1</issue><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">11740502</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Montgomery</surname><given-names>J M</given-names></name><name><surname>Selcher</surname><given-names>J C</given-names></name><name><surname>Hanson</surname><given-names>J E</given-names></name><name><surname>Madison</surname><given-names>D V</given-names></name></person-group><article-title>Dynamin-dependent NMDAR endocytosis during LTD and its dependence on synaptic state</article-title><source>BMC Neurosci</source><year>2005</year><volume>6</volume><fpage>48</fpage><pub-id pub-id-type="pmid">16042781</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name></person-group><article-title>Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons</article-title><source>Mol. Pharmacol</source><year>2007</year><volume>72</volume><issue>1</issue><fpage>40</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">17400762</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M G</given-names></name><name><surname>Toyoda</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>Y S</given-names></name><name><surname>Wu</surname><given-names>L J</given-names></name><name><surname>Ko</surname><given-names>S W</given-names></name><name><surname>Zhang</surname><given-names>X H</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Shum</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>B M</given-names></name><name><surname>Kaang</surname><given-names>B K</given-names></name><name><surname>Zhuo</surname><given-names>M</given-names></name></person-group><article-title>Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory</article-title><source>Neuron</source><year>2005</year><volume>47</volume><issue>6</issue><fpage>859</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16157280</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>T</given-names></name><name><surname>Komai</surname><given-names>S</given-names></name><name><surname>Watabe</surname><given-names>A M</given-names></name><name><surname>Kiyama</surname><given-names>Y</given-names></name><name><surname>Fukaya</surname><given-names>M</given-names></name><name><surname>Arima-Yoshida</surname><given-names>F</given-names></name><name><surname>Horai</surname><given-names>R</given-names></name><name><surname>Sudo</surname><given-names>K</given-names></name><name><surname>Ebine</surname><given-names>K</given-names></name><name><surname>Delawary</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>J</given-names></name><name><surname>Umemori</surname><given-names>H</given-names></name><name><surname>Tezuka</surname><given-names>T</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Manabe</surname><given-names>T</given-names></name></person-group><article-title>NR2B tyrosine phosphorylation modulates fear learning as well as amygdaloid synaptic plasticity</article-title><source>EMBO J</source><year>2006</year><volume>25</volume><issue>12</issue><fpage>2867</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">16710293</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Gardoni</surname><given-names>F</given-names></name><name><surname>Mauceri</surname><given-names>D</given-names></name><name><surname>Malinverno</surname><given-names>M</given-names></name><name><surname>Polli</surname><given-names>F</given-names></name><name><surname>Costa</surname><given-names>C</given-names></name><name><surname>Tozzi</surname><given-names>A</given-names></name><name><surname>Siliquini</surname><given-names>S</given-names></name><name><surname>Picconi</surname><given-names>B</given-names></name><name><surname>Cattabeni</surname><given-names>F</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name><name><surname>Di Luca</surname><given-names>M</given-names></name></person-group><article-title>Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression</article-title><source>J. Neurosci</source><year>2009</year><volume>29</volume><issue>3</issue><fpage>669</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">19158293</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y P</given-names></name><name><surname>Shimizu</surname><given-names>E</given-names></name><name><surname>Dube</surname><given-names>G R</given-names></name><name><surname>Rampon</surname><given-names>C</given-names></name><name><surname>Kerchner</surname><given-names>G A</given-names></name><name><surname>Zhuo</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Tsien</surname><given-names>J Z</given-names></name></person-group><article-title>Genetic enhancement of learning and memory in mice</article-title><source>Nature</source><year>1999</year><volume>401</volume><issue>6748</issue><fpage>63</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10485705</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Hawasli</surname><given-names>A H</given-names></name><name><surname>Benavides</surname><given-names>D R</given-names></name><name><surname>Nguyen</surname><given-names>C</given-names></name><name><surname>Kansy</surname><given-names>J W</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name><name><surname>Powell</surname><given-names>C M</given-names></name><name><surname>Cooper</surname><given-names>D C</given-names></name><name><surname>Bibb</surname><given-names>J A</given-names></name></person-group><article-title>Cyclin-dependent kinase 5 governs learning and synaptic plasticity <italic>via</italic> control of NMDAR degradation</article-title><source>Nat. Neurosci</source><year>2007</year><volume>10</volume><issue>7</issue><fpage>880</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17529984</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Fradley</surname><given-names>R L</given-names></name><name><surname>O'Meara</surname><given-names>G F</given-names></name><name><surname>Newman</surname><given-names>R J</given-names></name><name><surname>Andrieux</surname><given-names>A</given-names></name><name><surname>Job</surname><given-names>D</given-names></name><name><surname>Reynolds</surname><given-names>D S</given-names></name></person-group><article-title>STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating</article-title><source>Behav. Brain Res</source><year>2005</year><volume>163</volume><issue>2</issue><fpage>257</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">16046005</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Brigman</surname><given-names>J L</given-names></name><name><surname>Wright</surname><given-names>T</given-names></name><name><surname>Talani</surname><given-names>G</given-names></name><name><surname>Prasad-Mulcare</surname><given-names>S</given-names></name><name><surname>Jinde</surname><given-names>S</given-names></name><name><surname>Seabold</surname><given-names>G K</given-names></name><name><surname>Mathur</surname><given-names>P</given-names></name><name><surname>Davis</surname><given-names>M I</given-names></name><name><surname>Bock</surname><given-names>R</given-names></name><name><surname>Gustin</surname><given-names>R M</given-names></name><name><surname>Colbran</surname><given-names>R J</given-names></name><name><surname>Alvarez</surname><given-names>V A</given-names></name><name><surname>Nakazawa</surname><given-names>K</given-names></name><name><surname>Delpire</surname><given-names>E</given-names></name><name><surname>Lovinger</surname><given-names>D M</given-names></name><name><surname>Holmes</surname><given-names>A</given-names></name></person-group><article-title>Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning</article-title><source>J. Neurosci</source><year>2010</year><volume>30</volume><issue>13</issue><fpage>4590</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">20357110</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>K</given-names></name><name><surname>Quirk</surname><given-names>M C</given-names></name><name><surname>Chitwood</surname><given-names>R A</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Yeckel</surname><given-names>M F</given-names></name><name><surname>Sun</surname><given-names>L D</given-names></name><name><surname>Kato</surname><given-names>A</given-names></name><name><surname>Carr</surname><given-names>C A</given-names></name><name><surname>Johnston</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>M A</given-names></name><name><surname>Tonegawa</surname><given-names>S</given-names></name></person-group><article-title>Requirement for hippocampal CA3 NMDA receptors in associative memory recall</article-title><source>Science</source><year>2002</year><volume>297</volume><issue>5579</issue><fpage>211</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12040087</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Collingridge</surname><given-names>G L</given-names></name><name><surname>Bliss</surname><given-names>T V</given-names></name></person-group><article-title>Memories of NMDA receptors and LTP</article-title><source>Trends Neurosci</source><year>1995</year><volume>18</volume><issue>2</issue><fpage>54</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7537406</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Olney</surname><given-names>J W</given-names></name><name><surname>Farber</surname><given-names>N B</given-names></name></person-group><article-title>Glutamate receptor dysfunction and schizophrenia</article-title><source>Arch. Gen. Psychiatry</source><year>1995</year><volume>52</volume><issue>12</issue><fpage>998</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">7492260</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lissek</surname><given-names>S</given-names></name><name><surname>Gunturkun</surname><given-names>O</given-names></name></person-group><article-title>Maintenance in working memory or response selection? Functions of NMDA receptors in the pigeon
"prefrontal cortex"</article-title><source>Behav. Brain Res</source><year>2004</year><volume>153</volume><issue>2</issue><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">15265648</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>D W</given-names></name></person-group><article-title>Excitotoxic cell death</article-title><source>J. Neurobiol</source><year>1992</year><volume>23</volume><issue>9</issue><fpage>1261</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">1361523</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Querfurth</surname><given-names>H W</given-names></name><name><surname>LaFerla</surname><given-names>F M</given-names></name></person-group><article-title>Alzheimer's disease</article-title><source>N. Engl. J. Med</source><year>2010</year><volume>362</volume><issue>4</issue><fpage>329</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">20107219</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>C G</given-names></name><name><surname>Stoffler</surname><given-names>A</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse</article-title><source>Neuropharmacology</source><year>2007</year><volume>53</volume><issue>6</issue><fpage>699</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">17904591</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Uhasz</surname><given-names>G J</given-names></name><name><surname>Barkoczi</surname><given-names>B</given-names></name><name><surname>Vass</surname><given-names>G</given-names></name><name><surname>Datki</surname><given-names>Z</given-names></name><name><surname>Hunya</surname><given-names>A</given-names></name><name><surname> 
Fulop</surname><given-names>L</given-names></name><name><surname>Budai</surname><given-names>D</given-names></name><name><surname>Penke</surname><given-names>B</given-names></name><name><surname>Szegedi</surname><given-names>V</given-names></name></person-group><article-title>Fibrillar Abeta 
(1-42) enhances NMDA receptor sensitivity <italic>via</italic> the integrin signaling pathway</article-title><source>J. Alzheimer's Dis</source><year>2010</year><volume>19</volume><issue>3</issue><fpage>1055</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">20157259</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Alberdi</surname><given-names>E</given-names></name><name><surname>Sanchez-Gomez</surname><given-names>M V</given-names></name><name><surname>Cavaliere</surname><given-names>F</given-names></name><name><surname>Perez-Samartin</surname><given-names>A</given-names></name><name><surname>Zugaza</surname><given-names>J L</given-names></name><name><surname>Trullas</surname><given-names>R</given-names></name><name><surname>Domercq</surname><given-names>M</given-names></name><name><surname>Matute</surname><given-names>C</given-names></name></person-group><article-title>Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors</article-title><source>Cell Calcium</source><year>2010</year><volume>47</volume><issue>3</issue><fpage>264</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">20061018</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Butterfield</surname><given-names>D A</given-names></name><name><surname>Pocernich</surname><given-names>C B</given-names></name></person-group><article-title>The glutamatergic system and Alzheimer's disease: therapeutic implications</article-title><source>CNS Drugs</source><year>2003</year><volume>17</volume><issue>9</issue><fpage>641</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">12828500</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lesne</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>C</given-names></name><name><surname>Gabriel</surname><given-names>C</given-names></name><name><surname>Croci</surname><given-names>N</given-names></name><name><surname>MacKenzie</surname><given-names>E T</given-names></name><name><surname>Glabe</surname><given-names>C G</given-names></name><name><surname>Plotkine</surname><given-names>M</given-names></name><name><surname>Marchand-Verrecchia</surname><given-names>C</given-names></name><name><surname>Vivien</surname><given-names>D</given-names></name><name><surname>Buisson</surname><given-names>A</given-names></name></person-group><article-title>NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production</article-title><source>J. Neurosci</source><year>2005</year><volume>25</volume><issue>41</issue><fpage>9367</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">16221845</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Gordon-Krajcer</surname><given-names>W</given-names></name><name><surname>Salinska</surname><given-names>E</given-names></name><name><surname>Lazarewicz</surname><given-names>J W</given-names></name></person-group><article-title>N-methyl-d-aspartate receptor-mediated processing of beta-amyloid precursor protein in rat hippocampal slices: <italic>in vitro</italic>--superfusion study</article-title><source>Folia Neuropathol</source><year>2002</year><volume>40</volume><issue>1</issue><fpage>13</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12121034</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Uemura</surname><given-names>K</given-names></name><name><surname>Kuzuya</surname><given-names>A</given-names></name><name><surname>Maesako</surname><given-names>M</given-names></name><name><surname>Asada-Utsugi</surname><given-names>M</given-names></name><name><surname>Kubota</surname><given-names>M</given-names></name><name><surname>Aoyagi</surname><given-names>N</given-names></name><name><surname>Yoshioka</surname><given-names>K</given-names></name><name><surname>Okawa</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Kawamata</surname><given-names>J</given-names></name><name><surname>Shimohama</surname><given-names>S</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>R</given-names></name><name><surname>Kinoshita</surname><given-names>A</given-names></name></person-group><article-title>N-cadherin regulates p38 MAPK signaling <italic>via</italic> association 
with JNK-associated leucine zipper protein: implications for neurodegeneration in Alzheimer disease</article-title><source>J. Biol. Chem</source><year>2011</year><volume>286</volume><issue>9</issue><fpage>7619</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">21177868</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Nabeshima</surname><given-names>T</given-names></name></person-group><article-title>Changes in NMDA receptor/nitric oxide signaling pathway in the brain with aging</article-title><source>Microsc. Res. Tech</source><year>1998</year><volume>43</volume><issue>1</issue><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">9829461</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ikonomidou</surname><given-names>C</given-names></name><name><surname>Bosch</surname><given-names>F</given-names></name><name><surname>Miksa</surname><given-names>M</given-names></name><name><surname>Bittigau</surname><given-names>P</given-names></name><name><surname>Vockler</surname><given-names>J</given-names></name><name><surname>Dikranian</surname><given-names>K</given-names></name><name><surname>Tenkova</surname><given-names>T I</given-names></name><name><surname>Stefovska</surname><given-names>V</given-names></name><name><surname>Turski</surname><given-names>L</given-names></name><name><surname>Olney</surname><given-names>J W</given-names></name></person-group><article-title>Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain</article-title><source>Science</source><year>1999</year><volume>283</volume><issue>5398</issue><fpage>70</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9872743</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Fiske</surname><given-names>B K</given-names></name><name><surname>Brunjes</surname><given-names>P C</given-names></name></person-group><article-title>NMDA receptor regulation of cell death in the rat olfactory bulb</article-title><source>J. Neurobiol</source><year>2001</year><volume>47</volume><issue>3</issue><fpage>223</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11333403</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ikonomidou</surname><given-names>C</given-names></name><name><surname>Stefovska</surname><given-names>V</given-names></name><name><surname>Turski</surname><given-names>L</given-names></name></person-group><article-title>Neuronal death enhanced by N-methyl-D-aspartate antagonists</article-title><source>Proc. Natl. Acad. Sci. U. S. A</source><year>2000</year><volume>97</volume><issue>23</issue><fpage>12885</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">11058158</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Monti</surname><given-names>B</given-names></name><name><surname>Contestabile</surname><given-names>A</given-names></name></person-group><article-title>Blockade of the NMDA receptor increases developmental apoptotic elimination of granule neurons and activates caspases in the rat cerebellum</article-title><source>Eur. J. Neurosci</source><year>2000</year><volume>12</volume><issue>9</issue><fpage>3117</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">10998095</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ikonomidou</surname><given-names>C</given-names></name><name><surname>Bittigau</surname><given-names>P</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Genz</surname><given-names>K</given-names></name><name><surname>Hoerster</surname><given-names>F</given-names></name><name><surname>Felderhoff-Mueser</surname><given-names>U</given-names></name><name><surname>Tenkova</surname><given-names>T</given-names></name><name><surname>Dikranian</surname><given-names>K</given-names></name><name><surname>Olney</surname><given-names>J W</given-names></name></person-group><article-title>Neurotransmitters and apoptosis in the developing brain</article-title><source>Biochem. Pharmacol</source><year>2001</year><volume>62</volume><fpage>401</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">11448448</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>S M</given-names></name><name><surname>de Rivero Vaccari</surname><given-names>J C</given-names></name><name><surname>Corriveau</surname><given-names>R A</given-names></name></person-group><article-title>Pronounced cell death in the absence of NMDA receptors in the developing somatosensory thalamus</article-title><source>J. Neurosci</source><year>2004</year><volume>24</volume><issue>42</issue><fpage>9441</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">15496680</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>de Rivero Vaccari</surname><given-names>J C</given-names></name><name><surname>Casey</surname><given-names>G P</given-names></name><name><surname>Aleem</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>W 
M</given-names></name><name><surname>Corriveau</surname><given-names>R A</given-names></name></person-group><article-title>NMDA receptors promote survival in somatosensory relay nuclei by inhibiting Bax-dependent developmental cell death</article-title><source>Proc. Natl. Acad. Sci. U. S. A</source><year>2006</year><volume>103</volume><issue>45</issue><fpage>16971</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17077143</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>W J</given-names></name><name><surname>Won</surname><given-names>S J</given-names></name><name><surname>Ryu</surname><given-names>B R</given-names></name><name><surname>Gwag</surname><given-names>B J</given-names></name></person-group><article-title>Blockade of ionotropic glutamate receptors produces neuronal apoptosis through the Bax-cytochrome C-caspase pathway: the causative role of Ca<sup>2+</sup> deficiency</article-title><source>J. Neurochem</source><year>2003</year><volume>85</volume><issue>2</issue><fpage>525</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">12675929</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Hetman</surname><given-names>M</given-names></name><name><surname>Kharebava</surname><given-names>G</given-names></name></person-group><article-title>Survival signaling pathways activated by NMDA receptors</article-title><source>Curr. Top. Med. Chem</source><year>2006</year><volume>6</volume><issue>8</issue><fpage>787</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">16719817</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>H H</given-names></name><name><surname>Briem</surname><given-names>T</given-names></name><name><surname>Dzietko</surname><given-names>M</given-names></name><name><surname>Sifringer</surname><given-names>M</given-names></name><name><surname>Voss</surname><given-names>A</given-names></name><name><surname>Rzeski</surname><given-names>W</given-names></name><name><surname>Zdzisinska</surname><given-names>B</given-names></name><name><surname>Thor</surname><given-names>F</given-names></name><name><surname>Heumann</surname><given-names>R</given-names></name><name><surname>Stepulak</surname><given-names>A</given-names></name><name><surname>Bittigau</surname><given-names>P</given-names></name><name><surname>Ikonomidou</surname><given-names>C</given-names></name></person-group><article-title>Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain</article-title><source>Neurobiol. Dis</source><year>2004</year><volume>16</volume><issue>2</issue><fpage>440</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15193300</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>G</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Johnson</surname><given-names>K M</given-names></name></person-group><article-title>The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration</article-title><source>Neuropsychopharmacology</source><year>2008</year><volume>33</volume><issue>6</issue><fpage>1343</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">17637606</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Olney</surname><given-names>J W</given-names></name><name><surname>Wozniak</surname><given-names>D F</given-names></name><name><surname>Farber</surname><given-names>N B</given-names></name></person-group><article-title>Excitotoxic Neurodegeneration in Alzheimer Disease: New Hypothesis and New Therapeutic Strategies</article-title><source>Arch. Neurol</source><year>1997</year><volume>54</volume><fpage>1234</fpage><lpage>1240</lpage><pub-id pub-id-type="pmid">9341569</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Wozniak</surname><given-names>D F</given-names></name><name><surname>Dikranian</surname><given-names>K</given-names></name><name><surname>Ishimaru</surname><given-names>M J</given-names></name><name><surname>Nardi</surname><given-names>A</given-names></name><name><surname> 
Corso</surname><given-names>T D</given-names></name><name><surname>Tenkova</surname><given-names>T</given-names></name><name><surname>Olney</surname><given-names>J W</given-names></name><name><surname>Fix</surname><given-names>A S</given-names></name></person-group><article-title>Disseminated corticolimbic neuronal degeneration induced in rat brain by 
MK-801: potential relevance to Alzheimer's Disease</article-title><source>Neurobiol. Dis</source><year>1998</year><volume>5</volume><fpage>305</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">10069574</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Clayton</surname><given-names>D A</given-names></name><name><surname>Mesches</surname><given-names>M H</given-names></name><name><surname>Alvarez</surname><given-names>E</given-names></name><name><surname>Bickford</surname><given-names>P C</given-names></name><name><surname>Browning</surname><given-names>M D</given-names></name></person-group><article-title>A hippocampal NR2B deficit can mimic age-related changes in long-term potentiation and spatial learning in the Fischer 344 rat</article-title><source>J. Neurosci</source><year>2002</year><volume>22</volume><issue>9</issue><fpage>3628</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">11978838</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ossowska</surname><given-names>K</given-names></name><name><surname>Wolfarth</surname><given-names>S</given-names></name><name><surname>Schulze</surname><given-names>G</given-names></name><name><surname>Wardas</surname><given-names>J</given-names></name><name><surname>Pietraszek</surname><given-names>M</given-names></name><name><surname>Lorenc-Koci</surname><given-names>E</given-names></name><name><surname>Smialowska</surname><given-names>M</given-names></name><name><surname>Coper</surname><given-names>H</given-names></name></person-group><article-title>Decline in motor functions in aging is related to the loss of NMDA receptors</article-title><source>Brain Res</source><year>2001</year><volume>907</volume><issue>1-2</issue><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11430887</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>P F</given-names></name><name><surname>Darlington</surname><given-names>C L</given-names></name></person-group><article-title>Glutamate receptor subunits expression in memory-associated brain structures: regional variations and effects of aging</article-title><source>Synapse</source><year>2008</year><volume>62</volume><issue>11</issue><fpage>834</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">18720514</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Kuehl-Kovarik</surname><given-names>M C</given-names></name><name><surname>Magnusson</surname><given-names>K R</given-names></name><name><surname>Premkumar</surname><given-names>L S</given-names></name><name><surname>Partin</surname><given-names>K M</given-names></name></person-group><article-title>Electrophysiological analysis of NMDA receptor subunit changes in the aging mouse cortex</article-title><source>Mech. Ageing Dev</source><year>2000</year><volume>115</volume><issue>1-2</issue><fpage>39</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">10854628</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Clayton</surname><given-names>D A</given-names></name><name><surname>Grosshans</surname><given-names>D R</given-names></name><name><surname>Browning</surname><given-names>M D</given-names></name></person-group><article-title>Aging and surface expression of hippocampal NMDA receptors</article-title><source>J. Biol. Chem</source><year>2002</year><volume>277</volume><issue>17</issue><fpage>14367</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11891215</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S R</given-names></name><name><surname>Jensen</surname><given-names>R</given-names></name><name><surname>Kelsay</surname><given-names>R</given-names></name><name><surname>Shumaker</surname><given-names>M</given-names></name><name><surname>Bochart</surname><given-names>R</given-names></name><name><surname>Brim</surname><given-names>B</given-names></name><name><surname>Zamzow</surname><given-names>D</given-names></name><name><surname>Magnusson</surname><given-names>K R</given-names></name></person-group><article-title>Reducing expression of GluN1(0XX) subunit splice variants of the NMDA receptor interferes with spatial reference memory</article-title><source>Behav. Brain Res</source><year>2012</year><volume>230</volume><issue>2</issue><fpage>317</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">22360858</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Magnusson</surname><given-names>K R</given-names></name><name><surname>Brim</surname><given-names>B L</given-names></name><name><surname>Das</surname><given-names>S R</given-names></name></person-group><article-title>Selective vulnerabilities of N-methyl-D-aspartate (NMDA) receptors during brain aging</article-title><source>Frontiers Aging Neurosci</source><year>2010</year><volume>2</volume><fpage>11</fpage></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Boric</surname><given-names>K</given-names></name><name><surname>Munoz</surname><given-names>P</given-names></name><name><surname>Gallagher</surname><given-names>M</given-names></name><name><surname>Kirkwood</surname><given-names>A</given-names></name></person-group><article-title>Potential adaptive function for altered long-term potentiation mechanisms in aging hippocampus</article-title><source>J. Neurosci</source><year>2008</year><volume>28</volume><issue>32</issue><fpage>8034</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18685028</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Bodhinathan</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Foster</surname><given-names>T C</given-names></name></person-group><article-title>Intracellular redox state alters NMDA receptor response during aging through Ca2+/calmodulin-dependent protein kinase II</article-title><source>J. Neurosci</source><year>2010</year><volume>30</volume><issue>5</issue><fpage>1914</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">20130200</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Taffe</surname><given-names>M A</given-names></name><name><surname>Weed</surname><given-names>M R</given-names></name><name><surname>Gutierrez</surname><given-names>T</given-names></name><name><surname>Davis</surname><given-names>S A</given-names></name><name><surname>Gold</surname><given-names>L H</given-names></name></person-group><article-title>Differential muscarinic and NMDA contributions to visuo-spatial paired-associate learning in rhesus monkeys</article-title><source>Psychopharmacology (Berl)</source><year>2002</year><volume>160</volume><issue>3</issue><fpage>253</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">11889494</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Procter</surname><given-names>A W</given-names></name><name><surname>Wong</surname><given-names>E H</given-names></name><name><surname>Stratmann</surname><given-names>G C</given-names></name><name><surname>Lowe</surname><given-names>S L</given-names></name><name><surname>Bowen</surname><given-names>D M</given-names></name></person-group><article-title>Reduced glycine stimulation of [3H]MK-801 binding in Alzheimer's disease</article-title><source>J. Neurochem</source><year>1989</year><volume>53</volume><issue>3</issue><fpage> 
698</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">2569500</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Schaeffer</surname><given-names>E L</given-names></name><name><surname>Gattaz</surname><given-names>W F</given-names></name></person-group><article-title>Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme</article-title><source>Psychopharmacology (Berl)</source><year>2008</year><volume>198</volume><issue>1</issue><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">18392810</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name></person-group><article-title>Association between NR2B subunit gene (GRIN2B) promoter polymorphisms and sporadic Alzheimer's disease in the North Chinese population</article-title><source>Neurosci. Lett</source><year>2009</year><volume>450</volume><issue>3</issue><fpage>356</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">18983893</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>E M</given-names></name><name><surname>Nong</surname><given-names>Y</given-names></name><name><surname>Almeida</surname><given-names>C G</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Moran</surname><given-names>T</given-names></name><name><surname>Choi</surname><given-names>E Y</given-names></name><name><surname>Nairn</surname><given-names>A C</given-names></name><name><surname>Salter</surname><given-names>M W</given-names></name><name><surname>Lombroso</surname><given-names>P J</given-names></name><name><surname>Gouras</surname><given-names>G K</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name></person-group><article-title>Regulation of NMDA receptor trafficking by amyloid-beta</article-title><source>Nat. Neurosci</source><year>2005</year><volume>8</volume><issue>8</issue><fpage>1051</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16025111</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Auffret</surname><given-names>A</given-names></name><name><surname>Gautheron</surname><given-names>V</given-names></name><name><surname>Repici</surname><given-names>M</given-names></name><name><surname>Kraftsik</surname><given-names>R</given-names></name><name><surname>Mount</surname><given-names>H T</given-names></name><name><surname>Mariani</surname><given-names>J</given-names></name><name><surname>Rovira</surname><given-names>C</given-names></name></person-group><article-title>Age-dependent impairment of spine morphology and synaptic plasticity in hippocampal CA1 neurons of a presenilin 1 transgenic mouse model of Alzheimer's disease</article-title><source>J. Neurosci</source><year>2009</year><volume>29</volume><issue>32</issue><fpage>10144</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">19675248</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Auffret</surname><given-names>A</given-names></name><name><surname>Gautheron</surname><given-names>V</given-names></name><name><surname>Mattson</surname><given-names>M P</given-names></name><name><surname>Mariani</surname><given-names>J</given-names></name><name><surname>Rovira</surname><given-names>C</given-names></name></person-group><article-title>Progressive age-related impairment of the late long-term potentiation in Alzheimer's disease presenilin-1 mutant knock-in mice</article-title><source>J. Alzheimer's Dis</source><year>2010</year><volume>19</volume><issue>3</issue><fpage>1021</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">20157256</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Mishizen-Eberz</surname><given-names>A J</given-names></name><name><surname>Rissman</surname><given-names>R A</given-names></name><name><surname>Carter</surname><given-names>T L</given-names></name><name><surname>Ikonomovic</surname><given-names>M D</given-names></name><name><surname>Wolfe</surname><given-names>B B</given-names></name><name><surname>Armstrong</surname><given-names>D M</given-names></name></person-group><article-title>Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology</article-title><source>Neurobiol. Dis</source><year>2004</year><volume>15</volume><issue>1</issue><fpage>80</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">14751773</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Frank</surname><given-names>A</given-names></name><name><surname>Diez-Tejedor</surname><given-names>E</given-names></name><name><surname>Hernanz</surname><given-names>A</given-names></name></person-group><article-title>Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia</article-title><source>J. Neural Transm. Park. Dis. Dement. Sect</source><year>1993</year><volume>6</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8216758</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Fukushima</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>E</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Komatsu</surname><given-names>N</given-names></name><name><surname>Okamura</surname><given-names>N</given-names></name><name><surname>Koike</surname><given-names>K</given-names></name><name><surname>Koizumi</surname><given-names>H</given-names></name><name><surname>Kumakiri</surname><given-names>C</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Iyo</surname><given-names>M</given-names></name></person-group><article-title>Possible role of D-serine in the pathophysiology of Alzheimer's disease</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2004</year><volume>28</volume><issue>2</issue><fpage>385</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14751437</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>S L</given-names></name><name><surname>Bowen</surname><given-names>D M</given-names></name></person-group><article-title>Glutamic acid concentration in brains of patients with Alzheimer's disease</article-title><source>Biochem. Soc. Trans</source><year>1990</year><volume>18</volume><issue>3</issue><fpage>443</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">1973666</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Deutsch</surname><given-names>J A</given-names></name></person-group><article-title>The cholinergic synapse and the site of memory</article-title><source>Science</source><year>1971</year><volume>174</volume><issue>4011</issue><fpage>788</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">4330469</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Blokland</surname><given-names>A</given-names></name></person-group><article-title>Acetylcholine: a neurotransmitter for learning and memory?</article-title><source>Brain Res. Brain Res. Rev</source><year>1995</year><volume>21</volume><issue>3</issue><fpage>285</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">8806017</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Tariot</surname><given-names>P N</given-names></name></person-group><article-title>Pharmacologic models of Alzheimer's disease</article-title><source>Psychiatr. Clin. North Am</source><year>1991</year><volume>14</volume><issue>2</issue><fpage>287</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">2062722</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>T</given-names></name><name><surname>Fuld</surname><given-names>P</given-names></name><name><surname>Thal</surname><given-names>L</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Terry</surname><given-names>R</given-names></name></person-group><article-title>Significance of neurotransmitter abnormalities in Alzheimer's disease</article-title><source>Res. Publ. Assoc. Res. Nerv. Ment. Dis</source><year>1986</year><volume>64</volume><fpage>279</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">2873637</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Bierer</surname><given-names>L M</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Knott</surname><given-names>P J</given-names></name><name><surname>Carlin</surname><given-names>L S</given-names></name><name><surname>Purohit</surname><given-names>D P</given-names></name><name><surname>Perl</surname><given-names>D P</given-names></name><name><surname>Schmeidler</surname><given-names>J</given-names></name><name><surname>Kanof</surname><given-names>P</given-names></name><name><surname>Davis</surname><given-names>K L</given-names></name></person-group><article-title>Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits</article-title><source>J. Neurochem</source><year>1995</year><volume>64</volume><issue>2</issue><fpage>749</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">7830069</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lleo</surname><given-names>A</given-names></name><name><surname>Greenberg</surname><given-names>S M</given-names></name><name><surname>Growdon</surname><given-names>J H</given-names></name></person-group><article-title>Current pharmacotherapy for Alzheimer's disease</article-title><source>Annu. Rev. Med</source><year>2006</year><volume>57</volume><fpage>513</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">16409164</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Markram</surname><given-names>H</given-names></name><name><surname>Segal</surname><given-names>M</given-names></name></person-group><article-title>The inositol 1,4,5-trisphosphate pathway mediates cholinergic potentiation of rat hippocampal neuronal responses to NMDA</article-title><source>J. Physiol</source><year>1992</year><volume>447</volume><fpage>513</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">1593457</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Navakkode</surname><given-names>S</given-names></name><name><surname>Korte</surname><given-names>M</given-names></name></person-group><article-title>Cooperation between cholinergic and glutamatergic receptors are essential to induce BDNF-dependent long-lasting memory storage</article-title><source>Hippocampus</source><year>2012</year><volume>22</volume><issue>2</issue><fpage>335</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">21254300</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Flores-Hernandez</surname><given-names>J</given-names></name><name><surname>Salgado</surname><given-names>H</given-names></name><name><surname>De La Rosa</surname><given-names>V</given-names></name><name><surname>Avila-Ruiz</surname><given-names>T</given-names></name><name><surname>Torres-Ramirez</surname><given-names>O</given-names></name><name><surname>Lopez-Lopez</surname><given-names>G</given-names></name><name><surname>Atzori</surname><given-names>M</given-names></name></person-group><article-title>Cholinergic direct inhibition of N-methyl-D aspartate receptor-mediated currents in the rat neocortex</article-title><source>Synapse</source><year>2009</year><volume>63</volume><issue>4</issue><fpage>308</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">19140165</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Kihara</surname><given-names>T</given-names></name><name><surname>Hongo</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Kem</surname><given-names>W R</given-names></name><name><surname>Shimohama</surname><given-names>S</given-names></name><name><surname>Akaike</surname><given-names>A</given-names></name><name><surname>Niidome</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>H</given-names></name></person-group><article-title>Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors</article-title><source>Br. J. Pharmacol</source><year>2010</year><volume>161</volume><issue>1</issue><fpage>127</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">20718745</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Dou</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name></person-group><article-title>Regulation of the NMDA receptor-mediated synaptic response by acetylcholinesterase inhibitors and its impairment in an animal model of Alzheimer's disease</article-title><source>Neurobiol. Aging</source><year>2008</year><volume>29</volume><issue>12</issue><fpage>1795</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">17555845</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Marcello</surname><given-names>E</given-names></name><name><surname>Gardoni</surname><given-names>F</given-names></name><name><surname>Mauceri</surname><given-names>D</given-names></name><name><surname>Romorini</surname><given-names>S</given-names></name><name><surname>Jeromin</surname><given-names>A</given-names></name><name><surname>Epis</surname><given-names>R</given-names></name><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Cattabeni</surname><given-names>F</given-names></name><name><surname>Sala</surname><given-names>C</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name><name><surname>Di Luca</surname><given-names>M</given-names></name></person-group><article-title>Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity</article-title><source>J. Neurosci</source><year>2007</year><volume>27</volume><issue>7</issue><fpage>1682</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">17301176</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Hoey</surname><given-names>S E</given-names></name><name><surname>Williams</surname><given-names>R J</given-names></name><name><surname>Perkinton</surname><given-names>M S</given-names></name></person-group><article-title>Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production</article-title><source>J. Neurosci</source><year>2009</year><volume>29</volume><issue>14</issue><fpage>4442</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">19357271</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Shankar</surname><given-names>G M</given-names></name><name><surname>Bloodgood</surname><given-names>B L</given-names></name><name><surname>Townsend</surname><given-names>M</given-names></name><name><surname>Walsh</surname><given-names>D M</given-names></name><name><surname>Selkoe</surname><given-names>D J</given-names></name><name><surname>Sabatini</surname><given-names>B L</given-names></name></person-group><article-title>Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway</article-title><source>J. Neurosci</source><year>2007</year><volume>27</volume><issue>11</issue><fpage>2866</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">17360908</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Yamin</surname><given-names>G</given-names></name></person-group><article-title>NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus</article-title><source>J. Neurosci. Res</source><year>2009</year><volume>87</volume><issue>8</issue><fpage>1729</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">19170166</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Cisse</surname><given-names>M</given-names></name><name><surname>Halabisky</surname><given-names>B</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Devidze</surname><given-names>N</given-names></name><name><surname>Dubal</surname><given-names>D B</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Orr</surname><given-names>A</given-names></name><name><surname>Lotz</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>D H</given-names></name><name><surname>Hamto</surname><given-names>P</given-names></name><name><surname>Ho</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>G Q</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><article-title>Reversing EphB2 depletion rescues cognitive functions in Alzheimer model</article-title><source>Nature</source><year>2011</year><volume>469</volume><issue>7328</issue><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">21113149</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Kamenetz</surname><given-names>F</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Hsieh</surname><given-names>H</given-names></name><name><surname>Seabrook</surname><given-names>G</given-names></name><name><surname>Borchelt</surname><given-names>D</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Sisodia</surname><given-names>S</given-names></name><name><surname>Malinow</surname><given-names>R</given-names></name></person-group><article-title>APP processing and synaptic function</article-title><source>Neuron</source><year>2003</year><volume>37</volume><issue>6</issue><fpage>925</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">12670422</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Niidome</surname><given-names>T</given-names></name><name><surname>Akaike</surname><given-names>A</given-names></name><name><surname>Kihara</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>H</given-names></name></person-group><article-title>Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor</article-title><source>Biochem. Biophys. Res. Commun</source><year>2006</year><volume>351</volume><issue>1</issue><fpage>259</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">17054909</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Kurup</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Venkitaramani</surname><given-names>D V</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name><name><surname>Nairn</surname><given-names>A C</given-names></name><name><surname>Lombroso</surname><given-names>P J</given-names></name></person-group><article-title>A-Mediated NMDA Receptor Endocytosis in Alzheimer's Disease Involves Ubiquitination of the Tyrosine Phosphatase STEP61</article-title><source>J. Neurosci</source><year>2010</year><volume>30</volume><issue>17</issue><fpage>5948</fpage><lpage>5957</lpage><pub-id pub-id-type="pmid">20427654</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q S</given-names></name><name><surname>Wei</surname><given-names>W Z</given-names></name><name><surname>Shimahara</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>C W</given-names></name></person-group><article-title>Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus</article-title><source>Neurobiol. Learn. Mem</source><year>2002</year><volume>77</volume><issue>3</issue><fpage>354</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">11991763</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Watson</surname><given-names>J B</given-names></name><name><surname>Xie</surname><given-names>C W</given-names></name></person-group><article-title>Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation</article-title><source>J. Neurophysiol</source><year>2004</year><volume>92</volume><issue>5</issue><fpage>2853</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15212428</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Knobloch</surname><given-names>M</given-names></name><name><surname>Farinelli</surname><given-names>M</given-names></name><name><surname>Konietzko</surname><given-names>U</given-names></name><name><surname>Nitsch</surname><given-names>R M</given-names></name><name><surname>Mansuy</surname><given-names>I M</given-names></name></person-group><article-title>Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms</article-title><source>J. Neurosci</source><year>2007</year><volume>27</volume><issue>29</issue><fpage>7648</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">17634359</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Durakoglugil</surname><given-names>M S</given-names></name><name><surname>Xian</surname><given-names>X</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><article-title>ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling</article-title><source>Proc. Natl. Acad. Sci. U. S. A</source><year>2010</year><volume>107</volume><issue>26</issue><fpage>12011</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">20547867</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H S</given-names></name><name><surname>Lipton</surname><given-names>S A</given-names></name></person-group><article-title>The chemical biology of clinically tolerated NMDA receptor antagonists</article-title><source>J. Neurochem</source><year>2006</year><volume>97</volume><issue>6</issue><fpage>1611</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">16805772</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>R G</given-names></name><name><surname>Anderson</surname><given-names>E</given-names></name><name><surname>Lynch</surname><given-names>G S</given-names></name><name><surname>Baudry</surname><given-names>M</given-names></name></person-group><article-title>Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5</article-title><source>Nature</source><year>1986</year><volume>319</volume><issue>6056</issue><fpage>774</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2869411</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>N</given-names></name><name><surname>Aigner</surname><given-names>T G</given-names></name></person-group><article-title>The glycine/NMDA receptor antagonist HA-966 impairs visual recognition memory in rhesus monkeys</article-title><source>Brain Res</source><year>1996</year><volume>731</volume><issue>1-2</issue><fpage>72</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8883856</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Rowland</surname><given-names>L M</given-names></name><name><surname>Astur</surname><given-names>R S</given-names></name><name><surname>Jung</surname><given-names>R E</given-names></name><name><surname>Bustillo</surname><given-names>J R</given-names></name><name><surname>Lauriello</surname><given-names>J</given-names></name><name><surname>Yeo</surname><given-names>R A</given-names></name></person-group><article-title>Selective cognitive impairments associated with NMDA receptor blockade in humans</article-title><source>Neuropsychopharmacology</source><year>2005</year><volume>30</volume><issue>3</issue><fpage>633</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15647751</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>van der Staay</surname><given-names>F J</given-names></name><name><surname>Rutten</surname><given-names>K</given-names></name><name><surname>Erb</surname><given-names>C</given-names></name><name><surname>Blokland</surname><given-names>A</given-names></name></person-group><article-title>Effects of the cognition impairer MK-801 on learning and memory in mice and rats</article-title><source>Behav. Brain Res</source><year>2011</year><volume>220</volume><issue>1</issue><fpage>215</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">21310186</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Kos</surname><given-names>T</given-names></name><name><surname>Nikiforuk</surname><given-names>A</given-names></name><name><surname>Rafa</surname><given-names>D</given-names></name><name><surname>Popik</surname><given-names>P</given-names></name></person-group><article-title>The effects of NMDA receptor antagonists on attentional set-shifting task performance in mice</article-title><source>Psychopharmacology (Berl)</source><year>2011</year><volume>214</volume><issue>4</issue><fpage>911</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">21161188</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Reisberg</surname><given-names>B</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>St&#x000f6;ffler</surname><given-names>A</given-names></name><name><surname>Schmitt</surname><given-names>F</given-names></name><name><surname>Ferris</surname><given-names>S</given-names></name><name><surname>M&#x000f6;bius</surname><given-names>H J</given-names></name><name><surname>Group.</surname><given-names>t M S</given-names></name></person-group><article-title>Memantine in Moderate-to-Severe Alzheimer Disease</article-title><source>N. Engl. J. Med</source><year>2003</year><volume>348</volume><fpage>1333</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">12672860</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Scarpini</surname><given-names>E</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name></person-group><article-title>Treatment of Alzheimer's disease: current status and new perspectives</article-title><source>Lancet Neurol</source><year>2003</year><volume>2</volume><issue>9</issue><fpage>539</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">12941576</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Pall&#x000e0;s</surname><given-names>M</given-names></name><name><surname>Camins</surname><given-names>A</given-names></name></person-group><article-title>Molecular and Biochemical Features in Alzheimer disease</article-title><source>Curr. Pharm. Des</source><year>2006</year><volume>12</volume><fpage>4389</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">17105434</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Gardoni</surname><given-names>F</given-names></name><name><surname>Di Luca</surname><given-names>M</given-names></name></person-group><article-title>New targets for pharmacological intervention in the glutamatergic synapse</article-title><source>Eur. J. Pharmacol</source><year>2006</year><volume>545</volume><issue>1</issue><fpage>2</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">16831414</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>More</surname><given-names>L</given-names></name><name><surname>Gravius</surname><given-names>A</given-names></name><name><surname>Nagel</surname><given-names>J</given-names></name><name><surname>Valastro</surname><given-names>B</given-names></name><name><surname>Greco</surname><given-names>S</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats</article-title><source>Behav. Pharmacol</source><year>2008</year><volume>19</volume><issue>7</issue><fpage>724</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">18797249</pub-id></element-citation></ref><ref id="R106"><label>106</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>J T</given-names></name><name><surname>Puttfarcken</surname><given-names>P</given-names></name></person-group><article-title>Oxidative stress, glutamate, and neurodegenerative disorders</article-title><source>Science</source><year>1993</year><volume>262</volume><issue>5134</issue><fpage>689</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">7901908</pub-id></element-citation></ref><ref id="R107"><label>107</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C H</given-names></name><name><surname>Lane</surname><given-names>H Y</given-names></name><name><surname>Tsai</surname><given-names>G E</given-names></name></person-group><article-title>Glutamate signaling in the pathophysiology and therapy of schizophrenia</article-title><source>Pharmacol. Biochem. Behav</source><year>2012</year><volume>100</volume><issue>4</issue><fpage>665</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">21463651</pub-id></element-citation></ref><ref id="R108"><label>108</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>T M</given-names></name><name><surname>Pauly-Evers</surname><given-names>M</given-names></name><name><surname>Higgins</surname><given-names>G A</given-names></name><name><surname>Ouagazzal</surname><given-names>A M</given-names></name><name><surname>Mutel</surname><given-names>V</given-names></name><name><surname>Borroni</surname><given-names>E</given-names></name><name><surname>Kemp</surname><given-names>J A</given-names></name><name><surname>Bluethmann</surname><given-names>H</given-names></name><name><surname>Kew</surname><given-names>J N</given-names></name></person-group><article-title>Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity</article-title><source>J. Neurosci</source><year>2002</year><volume>22</volume><issue>15</issue><fpage>6713</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">12151550</pub-id></element-citation></ref><ref id="R109"><label>109</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Kew</surname><given-names>J N</given-names></name><name><surname>Koester</surname><given-names>A</given-names></name><name><surname>Moreau</surname><given-names>J L</given-names></name><name><surname>Jenck</surname><given-names>F</given-names></name><name><surname>Ouagazzal</surname><given-names>A M</given-names></name><name><surname>Mutel</surname><given-names>V</given-names></name><name><surname>Richards</surname><given-names>J G</given-names></name><name><surname>Trube</surname><given-names>G</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Montkowski</surname><given-names>A</given-names></name><name><surname>Hundt</surname><given-names>W</given-names></name><name><surname>Reinscheid</surname><given-names>R K</given-names></name><name><surname>Pauly-Evers</surname><given-names>M</given-names></name><name><surname>Kemp</surname><given-names>J A</given-names></name><name><surname>Bluethmann</surname><given-names>H</given-names></name></person-group><article-title>Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site</article-title><source>J. Neurosci</source><year>2000</year><volume>20</volume><issue>11</issue><fpage>4037</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">10818139</pub-id></element-citation></ref><ref id="R110"><label>110</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Flood</surname><given-names>J F</given-names></name><name><surname>Morley</surname><given-names>J E</given-names></name><name><surname>Lanthorn</surname><given-names>T H</given-names></name></person-group><article-title>Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor</article-title><source>Eur. J. Pharmacol</source><year>1992</year><volume>221</volume><issue>2-3</issue><fpage>249</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">1330624</pub-id></element-citation></ref><ref id="R111"><label>111</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname><given-names>G M</given-names></name><name><surname>Schmidt</surname><given-names>W J</given-names></name></person-group><article-title>D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task</article-title><source>Eur. J. Pharmacol</source><year>1992</year><volume>224</volume><issue>1</issue><fpage>97</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1451747</pub-id></element-citation></ref><ref id="R112"><label>112</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>L T</given-names></name><name><surname>Moskal</surname><given-names>J R</given-names></name><name><surname>Disterhoft</surname><given-names>J F</given-names></name></person-group><article-title>Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine</article-title><source>Nature</source><year>1992</year><volume>359</volume><issue>6396</issue><fpage>638</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">1406995</pub-id></element-citation></ref><ref id="R113"><label>113</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Randolph</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>J W</given-names></name><name><surname>Tierney</surname><given-names>M C</given-names></name><name><surname>Bravi</surname><given-names>D</given-names></name><name><surname>Mouradian</surname><given-names>M M</given-names></name><name><surname>Chase</surname><given-names>T N</given-names></name></person-group><article-title>D-cycloserine treatment of Alzheimer disease</article-title><source>Alzheimer Dis. Assoc. Disord</source><year>1994</year><volume>8</volume><issue>3</issue><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">7986489</pub-id></element-citation></ref><ref id="R114"><label>114</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>G E</given-names></name><name><surname>Falk</surname><given-names>W E</given-names></name><name><surname>Gunther</surname><given-names>J</given-names></name></person-group><article-title>A preliminary study of D-cycloserine treatment in Alzheimer's disease</article-title><source>J. Neuropsychiatry Clin. Neurosci</source><year>1998</year><volume>10</volume><issue>2</issue><fpage>224</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9608414</pub-id></element-citation></ref><ref id="R115"><label>115</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>G E</given-names></name><name><surname>Falk</surname><given-names>W E</given-names></name><name><surname>Gunther</surname><given-names>J</given-names></name><name><surname>Coyle</surname><given-names>J T</given-names></name></person-group><article-title>Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment</article-title><source>Am. J. Psychiatry</source><year>1999</year><volume>156</volume><issue>3</issue><fpage>467</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10080566</pub-id></element-citation></ref><ref id="R116"><label>116</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Fakouhi</surname><given-names>T D</given-names></name><name><surname>Jhee</surname><given-names>S S</given-names></name><name><surname>Sramek</surname><given-names>J J</given-names></name><name><surname>Benes</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>P</given-names></name><name><surname>Hantsburger</surname><given-names>G</given-names></name><name><surname>Herting</surname><given-names>R</given-names></name><name><surname>Swabb</surname><given-names>E A</given-names></name><name><surname>Cutler</surname><given-names>N R</given-names></name></person-group><article-title>Evaluation of cycloserine in the treatment of Alzheimer's disease</article-title><source>J. Geriatr. Psychiatry Neurol</source><year>1995</year><volume>8</volume><issue>4</issue><fpage>226</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">8561836</pub-id></element-citation></ref><ref id="R117"><label>117</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Mohr</surname><given-names>E</given-names></name><name><surname>Knott</surname><given-names>V</given-names></name><name><surname>Sampson</surname><given-names>M</given-names></name><name><surname>Wesnes</surname><given-names>K</given-names></name><name><surname>Herting</surname><given-names>R</given-names></name><name><surname>Mendis</surname><given-names>T</given-names></name></person-group><article-title>Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease</article-title><source>Clin. Neuropharmacol</source><year>1995</year><volume>18</volume><issue>1</issue><fpage>28</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">8665532</pub-id></element-citation></ref><ref id="R118"><label>118</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Moskal</surname><given-names>J R</given-names></name><name><surname>Kuo</surname><given-names>A G</given-names></name><name><surname>Weiss</surname><given-names>C</given-names></name><name><surname>Wood</surname><given-names>P L</given-names></name><name><surname>O'Connor Hanson</surname><given-names>A</given-names></name><name><surname>Kelso</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>R B</given-names></name><name><surname>Disterhoft</surname><given-names>J F</given-names></name></person-group><article-title>GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator</article-title><source>Neuropharmacology</source><year>2005</year><volume>49</volume><issue>7</issue><fpage>1077</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">16051282</pub-id></element-citation></ref><ref id="R119"><label>119</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Burgdorf</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X L</given-names></name><name><surname>Weiss</surname><given-names>C</given-names></name><name><surname>Matthews</surname><given-names>E</given-names></name><name><surname>Disterhoft</surname><given-names>J F</given-names></name><name><surname>Stanton</surname><given-names>P K</given-names></name><name><surname>Moskal</surname><given-names>J R</given-names></name></person-group><article-title>The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats</article-title><source>Neurobiol. Aging</source><year>2011</year><volume>32</volume><issue>4</issue><fpage>698</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">19446371</pub-id></element-citation></ref><ref id="R120"><label>120</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Finkel</surname><given-names>S</given-names></name></person-group><article-title>Behavioral and psychologic symptoms of dementia</article-title><source>Clin. Geriatr. Med</source><year>2003</year><volume>19</volume><issue>4</issue><fpage>799</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">15024813</pub-id></element-citation></ref><ref id="R121"><label>121</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>A</given-names></name><name><surname>Jacoby</surname><given-names>R</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name></person-group><article-title>Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content</article-title><source>Br. J. Psychiatry</source><year>1990</year><volume>157 72-6</volume><fpage>92</fpage><lpage>4</lpage></element-citation></ref><ref id="R122"><label>122</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>A</given-names></name><name><surname>Jacoby</surname><given-names>R</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name></person-group><article-title>Psychiatric phenomena in Alzheimer's disease. II: Disorders of perception</article-title><source>Br. J. Psychiatry</source><year>1990</year><volume>157</volume><fpage>76</fpage><lpage>81</lpage><fpage>92</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">2397366</pub-id></element-citation></ref><ref id="R123"><label>123</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>A</given-names></name><name><surname>Jacoby</surname><given-names>R</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name></person-group><article-title>Psychiatric phenomena in Alzheimer's disease. III: Disorders of mood</article-title><source>Br. J. Psychiatry</source><year>1990</year><volume>157 81-6</volume><fpage>92</fpage><lpage>4</lpage></element-citation></ref><ref id="R124"><label>124</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>J</given-names></name></person-group><article-title>Behavioral symptoms in vascular cognitive impairment and vascular dementia</article-title><source>Int. Psychogeriatr</source><year>2003</year><volume>15</volume><issue>Suppl 1</issue><fpage> 
133</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16191230</pub-id></element-citation></ref><ref id="R125"><label>125</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J M</given-names></name><name><surname>Lyons</surname><given-names>D</given-names></name><name><surname>Shin</surname><given-names>I S</given-names></name><name><surname>Yoon</surname><given-names>J S</given-names></name></person-group><article-title>Differences in the behavioral and psychological symptoms between Alzheimer's disease and vascular dementia: are the different pharmacologic treatment strategies justifiable?</article-title><source>Hum. Psychopharmacol</source><year>2003</year><volume>18</volume><issue>3</issue><fpage>215</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12672174</pub-id></element-citation></ref><ref id="R126"><label>126</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Savva</surname><given-names>G M</given-names></name><name><surname>Zaccai</surname><given-names>J</given-names></name><name><surname>Matthews</surname><given-names>F E</given-names></name><name><surname>Davidson</surname><given-names>J E</given-names></name><name><surname>McKeith</surname><given-names>I</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name></person-group><article-title>Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population</article-title><source>Br. J. Psychiatry</source><year>2009</year><volume>194</volume><issue>3</issue><fpage>212</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19252147</pub-id></element-citation></ref><ref id="R127"><label>127</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Paulsen</surname><given-names>J S</given-names></name><name><surname>Salmon</surname><given-names>D P</given-names></name><name><surname>Thal</surname><given-names>L J</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Weisstein-Jenkins</surname><given-names>C</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Hofstetter</surname><given-names>C R</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Grant</surname><given-names>I</given-names></name><name><surname>Jeste</surname><given-names>D V</given-names></name></person-group><article-title>Incidence of and risk factors for hallucinations and delusions in patients with probable AD</article-title><source>Neurology</source><year>2000</year><volume>54</volume><issue>10</issue><fpage>1965</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">10822438</pub-id></element-citation></ref><ref id="R128"><label>128</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Devanand</surname><given-names>D P</given-names></name></person-group><article-title>Behavioral complications and their treatment in Alzheimer's disease</article-title><source>Geriatrics</source><year>1997</year><volume>52 Suppl 2</volume><fpage>S37</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9307585</pub-id></element-citation></ref><ref id="R129"><label>129</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>M</given-names></name><name><surname>Shao</surname><given-names>H</given-names></name><name><surname>Zandi</surname><given-names>P</given-names></name><name><surname>Lyketsos</surname><given-names>C G</given-names></name><name><surname>Welsh-Bohmer</surname><given-names>K A</given-names></name><name><surname>Norton</surname><given-names>M C</given-names></name><name><surname>Breitner</surname><given-names>J C</given-names></name><name><surname>Steffens</surname><given-names>D C</given-names></name><name><surname>Tschanz</surname><given-names>J T</given-names></name></person-group><article-title>Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study</article-title><source>Int. J. Geriatr. Psychiatry</source><year>2008</year><volume>23</volume><issue>2</issue><fpage>170</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17607801</pub-id></element-citation></ref><ref id="R130"><label>130</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>C</given-names></name><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Trollor</surname><given-names>J</given-names></name><name><surname>Sachdev</surname><given-names>P</given-names></name></person-group><article-title>Behavioral and psychological symptoms associated with dementia subtype and severity</article-title><source>Int. Psychogeriatr</source><year>2010</year><volume>22</volume><issue>2</issue><fpage>300</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19906327</pub-id></element-citation></ref><ref id="R131"><label>131</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Agosti</surname><given-names>C</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name></person-group><article-title>Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment</article-title><source>Arch. Gerontol. Geriatr</source><year>2008</year><volume>46</volume><issue>1</issue><fpage>101</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17467082</pub-id></element-citation></ref><ref id="R132"><label>132</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Hersch</surname><given-names>E C</given-names></name><name><surname>Falzgraf</surname><given-names>S</given-names></name></person-group><article-title>Management of the behavioral and psychological symptoms of dementia</article-title><source>Clin. Interven. Aging</source><year>2007</year><volume>2</volume><issue>4</issue><fpage>611</fpage><lpage>21</lpage></element-citation></ref><ref id="R133"><label>133</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Dalvi</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>T</given-names></name></person-group><article-title>Is there a need to study behavioral and psychological signs and symptoms of dementia across cultures?</article-title><source>Int. Psychogeriatr</source><year>2005</year><volume>17</volume><issue>3</issue><fpage>513</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16252382</pub-id></element-citation></ref><ref id="R134"><label>134</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Bourgeois</surname><given-names>M S</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Burgio</surname><given-names>L</given-names></name></person-group><article-title>Interventions for caregivers of patients with Alzheimer's disease: a review and analysis of content, process, and outcomes</article-title><source>Int. J. Aging Hum. Dev</source><year>1996</year><volume>43</volume><issue>1</issue><fpage>35</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">8886875</pub-id></element-citation></ref><ref id="R135"><label>135</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Deimling</surname><given-names>G T</given-names></name><name><surname>Bass</surname><given-names>D M</given-names></name></person-group><article-title>Symptoms of mental impairment among elderly adults and their effects on family caregivers</article-title><source>J. Gerontol</source><year>1986</year><volume>41</volume><issue>6</issue><fpage>778</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">3772056</pub-id></element-citation></ref><ref id="R136"><label>136</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Rabins</surname><given-names>P V</given-names></name><name><surname>Mace</surname><given-names>N L</given-names></name><name><surname>Lucas</surname><given-names>M J</given-names></name></person-group><article-title>The impact of dementia on the family</article-title><source>JAMA</source><year>1982</year><volume>248</volume><issue>3</issue><fpage>333</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7087127</pub-id></element-citation></ref><ref id="R137"><label>137</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Draper</surname><given-names>B</given-names></name><name><surname>Snowdon</surname><given-names>J</given-names></name><name><surname>Meares</surname><given-names>S</given-names></name><name><surname>Turner</surname><given-names>J</given-names></name><name><surname>Gonski</surname><given-names>P</given-names></name><name><surname>McMinn</surname><given-names>B</given-names></name><name><surname>McIntosh</surname><given-names>H</given-names></name><name><surname>Latham</surname><given-names>L</given-names></name><name><surname>Draper</surname><given-names>D</given-names></name><name><surname>Luscombe</surname><given-names>G</given-names></name></person-group><article-title>Case-controlled study of nursing home residents referred for treatment of vocally disruptive behavior</article-title><source>Int. Psychogeriatr</source><year>2000</year><volume>12</volume><issue>3</issue><fpage>333</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">11081953</pub-id></element-citation></ref><ref id="R138"><label>138</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Rodney</surname><given-names>V</given-names></name></person-group><article-title>Nurse stress associated with aggression in people with dementia: its relationship to hardiness, cognitive appraisal and coping</article-title><source>J. Adv. Nurs</source><year>2000</year><volume>31</volume><issue>1</issue><fpage>172</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10632806</pub-id></element-citation></ref><ref id="R139"><label>139</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Sink</surname><given-names>K M</given-names></name><name><surname>Holden</surname><given-names>K F</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name></person-group><article-title>Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence</article-title><source>JAMA</source><year>2005</year><volume>293</volume><issue>5</issue><fpage>596</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">15687315</pub-id></element-citation></ref><ref id="R140"><label>140</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>P E</given-names></name><name><surname>Gill</surname><given-names>S S</given-names></name><name><surname>Freedman</surname><given-names>M</given-names></name><name><surname>Bronskill</surname><given-names>S E</given-names></name><name><surname>Hillmer</surname><given-names>M P</given-names></name><name><surname>Rochon</surname><given-names>P A</given-names></name></person-group><article-title>Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review</article-title><source>BMJ</source><year>2004</year><volume>329</volume><issue>7457</issue><fpage>75</fpage><pub-id pub-id-type="pmid">15194601</pub-id></element-citation></ref><ref id="R141"><label>141</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Corbett</surname><given-names>A</given-names></name><name><surname>Chitramohan</surname><given-names>R</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name></person-group><article-title>Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions</article-title><source>Curr. Opin. Psychiatry</source><year>2009</year><volume>22</volume><issue>6</issue><fpage>532</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">19696673</pub-id></element-citation></ref><ref id="R142"><label>142</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>L S</given-names></name><name><surname>Tariot</surname><given-names>P N</given-names></name><name><surname>Dagerman</surname><given-names>K S</given-names></name><name><surname>Davis</surname><given-names>S M</given-names></name><name><surname>Hsiao</surname><given-names>J K</given-names></name><name><surname>Ismail</surname><given-names>M S</given-names></name><name><surname>Lebowitz</surname><given-names>B D</given-names></name><name><surname>Lyketsos</surname><given-names>C G</given-names></name><name><surname>Ryan</surname><given-names>J M</given-names></name><name><surname>Stroup</surname><given-names>T S</given-names></name><name><surname>Sultzer</surname><given-names>D L</given-names></name><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Lieberman</surname><given-names>J A</given-names></name></person-group><article-title>Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease</article-title><source>N. Engl. J. Med</source><year>2006</year><volume>355</volume><issue>15</issue><fpage>1525</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">17035647</pub-id></element-citation></ref><ref id="R143"><label>143</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Vigen</surname><given-names>C L</given-names></name><name><surname>Mack</surname><given-names>W J</given-names></name><name><surname>Keefe</surname><given-names>R S</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Sultzer</surname><given-names>D L</given-names></name><name><surname>Stroup</surname><given-names>T S</given-names></name><name><surname>Dagerman</surname><given-names>K S</given-names></name><name><surname>Hsiao</surname><given-names>J K</given-names></name><name><surname>Lebowitz</surname><given-names>B D</given-names></name><name><surname>Lyketsos</surname><given-names>C G</given-names></name><name><surname>Tariot</surname><given-names>P N</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Schneider</surname><given-names>L S</given-names></name></person-group><article-title>Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD</article-title><source>Am. J. Psychiatry</source><year>2011</year><volume>168</volume><issue>8</issue><fpage>831</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21572163</pub-id></element-citation></ref><ref id="R144"><label>144</label><element-citation publication-type="other" publisher-type="web"><collab>Food Drug Administration</collab><article-title>Deaths with Antipsychotics in Elderly
Patients with Behavioral Disturbances</article-title><source>FDA Public Health Advisory</source><comment><uri xlink:type="simple" xlink:href="http://www.fda.gov/cder/drug/advisory/antipsychotics.htm">http://www.fda.gov/cder/drug/advisory/antipsychotics.htm</uri></comment><year>2008</year><date-in-citation content-type="access-date">Accessed on: 30th December, 2008</date-in-citation></element-citation></ref><ref id="R145"><label>145</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>L S</given-names></name><name><surname>Dagerman</surname><given-names>K S</given-names></name><name><surname>Insel</surname><given-names>P</given-names></name></person-group><article-title>Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials</article-title><source>JAMA</source><year>2005</year><volume>294</volume><issue>15</issue><fpage>1934</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16234500</pub-id></element-citation></ref><ref id="R146"><label>146</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P S</given-names></name><name><surname>Schneeweiss</surname><given-names>S</given-names></name><name><surname>Avorn</surname><given-names>J</given-names></name><name><surname>Fischer</surname><given-names>M A</given-names></name><name><surname>Mogun</surname><given-names>H</given-names></name><name><surname>Solomon</surname><given-names>D H</given-names></name><name><surname>Brookhart</surname><given-names>M A</given-names></name></person-group><article-title>Risk of death in elderly
users of conventional vs. atypical antipsychotic medications</article-title><source>N. Engl. J. Med</source><year>2005</year><volume>353</volume><issue>22</issue><fpage>2335</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16319382</pub-id></element-citation></ref><ref id="R147"><label>147</label><element-citation publication-type="other" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Waite</surname><given-names>J</given-names></name></person-group><article-title>The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease</article-title><source>Cochrane Database Syst. Rev</source><year>2006</year><issue>1</issue><fpage>CD003476</fpage><pub-id pub-id-type="pmid">16437455</pub-id></element-citation></ref><ref id="R148"><label>148</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>M F</given-names></name><name><surname>Martin-Cook</surname><given-names>K</given-names></name><name><surname>Foster</surname><given-names>B M</given-names></name><name><surname>Saine</surname><given-names>K</given-names></name><name><surname>Fontaine</surname><given-names>C S</given-names></name><name><surname>Svetlik</surname><given-names>D A</given-names></name></person-group><article-title>Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients</article-title><source>J. Clin. Psychiatry</source><year>2000</year><volume>61</volume><issue>7</issue><fpage>487</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">10937606</pub-id></element-citation></ref><ref id="R149"><label>149</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Hecker</surname><given-names>J</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Ames</surname><given-names>D</given-names></name><name><surname>Subbiah</surname><given-names>P</given-names></name><name><surname>Whalen</surname><given-names>E</given-names></name><name><surname>Emir</surname><given-names>B</given-names></name></person-group><article-title>Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease</article-title><source>Int. Psychogeriatr</source><year>2002</year><volume>14</volume><issue>4</issue><fpage>389</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">12670060</pub-id></element-citation></ref><ref id="R150"><label>150</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Paleacu</surname><given-names>D</given-names></name><name><surname>Mazeh</surname><given-names>D</given-names></name><name><surname>Mirecki</surname><given-names>I</given-names></name><name><surname>Even</surname><given-names>M</given-names></name><name><surname>Barak</surname><given-names>Y</given-names></name></person-group><article-title>Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease</article-title><source>Clin. Neuropharmacol</source><year>2002</year><volume>25</volume><issue>6</issue><fpage>313</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12469005</pub-id></element-citation></ref><ref id="R151"><label>151</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Bergman</surname><given-names>J</given-names></name><name><surname>Brettholz</surname><given-names>I</given-names></name><name><surname>Shneidman</surname><given-names>M</given-names></name><name><surname>Lerner</surname><given-names>V</given-names></name></person-group><article-title>Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type</article-title><source>Clin. Neuropharmacol</source><year>2003</year><volume>26</volume><issue>2</issue><fpage> 
88</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">12671528</pub-id></element-citation></ref><ref id="R152"><label>152</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Wilkinson</surname><given-names>D</given-names></name><name><surname>Dean</surname><given-names>C</given-names></name><name><surname>Vethanayagam</surname><given-names>S</given-names></name><name><surname>Olivieri</surname><given-names>S</given-names></name><name><surname>Langley</surname><given-names>A</given-names></name><name><surname>Pandita-Gunawardena</surname><given-names>N D</given-names></name><name><surname>Hogg</surname><given-names>F</given-names></name><name><surname>Clare</surname><given-names>C</given-names></name><name><surname>Damms</surname><given-names>J</given-names></name></person-group><article-title>The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease</article-title><source>Neurology</source><year>2004</year><volume>63</volume><issue>2</issue><fpage>214</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15277611</pub-id></element-citation></ref><ref id="R153"><label>153</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>J L</given-names></name><name><surname>McRae</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name></person-group><article-title>Effects of donepezil 
on neuropsychiatric symptoms in patients with dementia and 
severe behavioral disorders</article-title><source>Am. J. Geriatr. Psychiatry</source><year>2006</year><volume>14</volume><issue>7</issue><fpage>605</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">16816014</pub-id></element-citation></ref><ref id="R154"><label>154</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>R J</given-names></name><name><surname>Juszczak</surname><given-names>E</given-names></name><name><surname>Ballard</surname><given-names>C G</given-names></name><name><surname>Bentham</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>R G</given-names></name><name><surname>Bullock</surname><given-names>R</given-names></name><name><surname>Burns</surname><given-names>A S</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Jacoby</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>T</given-names></name><name><surname>Knapp</surname><given-names>M</given-names></name><name><surname>Lindesay</surname><given-names>J</given-names></name><name><surname>O'Brien</surname><given-names>J T</given-names></name><name><surname>Wilcock</surname><given-names>G</given-names></name><name><surname>Katona</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>R W</given-names></name><name><surname>DeCesare</surname><given-names>J</given-names></name><name><surname>Rodger</surname><given-names>M</given-names></name></person-group><article-title>Donepezil for the treatment of agitation in Alzheimer's disease</article-title><source>N. Engl. J. Med</source><year>2007</year><volume>357</volume><issue>14</issue><fpage>1382</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">17914039</pub-id></element-citation></ref><ref id="R155"><label>155</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Pelosi</surname><given-names>A</given-names></name></person-group><article-title>Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease</article-title><source>Evid. Based Ment. Health</source><year>2008</year><volume>11</volume><issue>3</issue><fpage>84</fpage><pub-id pub-id-type="pmid">18669686</pub-id></element-citation></ref><ref id="R156"><label>156</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Reekum</surname><given-names>R</given-names></name></person-group><article-title>Donepezil was no better than placebo for agitation in patients with Alzheimer disease</article-title><source>ACP J. Club</source><year>2008</year><volume>148</volume><issue>2</issue><fpage>33</fpage><pub-id pub-id-type="pmid">18311863</pub-id></element-citation></ref><ref id="R157"><label>157</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Carrasco</surname><given-names>M M</given-names></name><name><surname>Aguera</surname><given-names>L</given-names></name><name><surname>Gil</surname><given-names>P</given-names></name><name><surname>Morinigo</surname><given-names>A</given-names></name><name><surname>Leon</surname><given-names>T</given-names></name></person-group><article-title>Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease</article-title><source>Alzheimer Dis. Assoc. Disord</source><year>2011</year><volume>25</volume><issue>4</issue><fpage>333</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">21399485</pub-id></element-citation></ref><ref id="R158"><label>158</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Tariot</surname><given-names>P N</given-names></name><name><surname>Solomon</surname><given-names>P R</given-names></name><name><surname>Morris</surname><given-names>J C</given-names></name><name><surname>Kershaw</surname><given-names>P</given-names></name><name><surname>Lilienfeld</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name></person-group><article-title>A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study
Group</article-title><source>Neurology</source><year>2000</year><volume>54</volume><issue>12</issue><fpage>2269</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">10881251</pub-id></element-citation></ref><ref id="R159"><label>159</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Rockwood</surname><given-names>K</given-names></name><name><surname>Mintzer</surname><given-names>J</given-names></name><name><surname>Truyen</surname><given-names>L</given-names></name><name><surname>Wessel</surname><given-names>T</given-names></name><name><surname>Wilkinson</surname><given-names>D</given-names></name></person-group><article-title>Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2001</year><volume>71</volume><issue>5</issue><fpage>589</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">11606667</pub-id></element-citation></ref><ref id="R160"><label>160</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Monsch</surname><given-names>A U</given-names></name><name><surname>Giannakopoulos</surname><given-names>P</given-names></name></person-group><article-title>Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease</article-title><source>Curr. Med. Res. Opin</source><year>2004</year><volume>20</volume><issue>6</issue><fpage>931</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15200752</pub-id></element-citation></ref><ref id="R161"><label>161</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Rabheru</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Binder</surname><given-names>C</given-names></name></person-group><article-title>Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials</article-title><source>Am. J. Geriatr. Psychiatry</source><year>2005</year><volume>13</volume><issue>6</issue><fpage>527</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">15956273</pub-id></element-citation></ref><ref id="R162"><label>162</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Finkel</surname><given-names>S I</given-names></name></person-group><article-title>Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease</article-title><source>Clin. Ther</source><year>2004</year><volume>26</volume><issue>7</issue><fpage>980</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">15336465</pub-id></element-citation></ref><ref id="R163"><label>163</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>J L</given-names></name><name><surname>Koumaras</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Mirski</surname><given-names>D</given-names></name></person-group><article-title>Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study</article-title><source>Am. J. Geriatric Pharmacother</source><year>2005</year><volume>3</volume><issue>3</issue><fpage>137</fpage><lpage>48</lpage></element-citation></ref><ref id="R164"><label>164</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>K</given-names></name><name><surname>Koumaras</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Gunay</surname><given-names>I</given-names></name><name><surname>Mirski</surname><given-names>D</given-names></name></person-group><article-title>Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer's disease : results of a 52-week open-label study</article-title><source>Clin. Drug Investig</source><year>2005</year><volume>25</volume><issue>8</issue><fpage>507</fpage><lpage>15</lpage></element-citation></ref><ref id="R165"><label>165</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Juby</surname><given-names>A</given-names></name><name><surname>Rehel</surname><given-names>B</given-names></name><name><surname>Schecter</surname><given-names>R</given-names></name></person-group><article-title>EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease</article-title><source>Int. J. Clin. Pract</source><year>2007</year><volume>61</volume><issue>6</issue><fpage>886</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">17504350</pub-id></element-citation></ref><ref id="R166"><label>166</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Kaufer</surname><given-names>D I</given-names></name><name><surname>Cummings</surname><given-names>J L</given-names></name><name><surname>Christine</surname><given-names>D</given-names></name></person-group><article-title>Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study</article-title><source>J. Geriatr. Psychiatry Neurol</source><year>1996</year><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8679057</pub-id></element-citation></ref><ref id="R167"><label>167</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Trinh</surname><given-names>N H</given-names></name><name><surname>Hoblyn</surname><given-names>J</given-names></name><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name></person-group><article-title>Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis</article-title><source>JAMA</source><year>2003</year><volume>289</volume><issue>2</issue><fpage>210</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12517232</pub-id></element-citation></ref><ref id="R168"><label>168</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Madhusoodanan</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Brenner</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name></person-group><article-title>Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach?</article-title><source>CNS Drugs</source><year>2007</year><volume>21</volume><issue>2</issue><fpage>101</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">17284093</pub-id></element-citation></ref><ref id="R169"><label>169</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Konovalov</surname><given-names>S</given-names></name><name><surname>Muralee</surname><given-names>S</given-names></name><name><surname>Tampi</surname><given-names>R R</given-names></name></person-group><article-title>Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review</article-title><source>Int. Psychogeriatr</source><year>2008</year><volume>20</volume><issue>2</issue><fpage>293</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">18047764</pub-id></element-citation></ref><ref id="R170"><label>170</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Grassi</surname><given-names>M</given-names></name><name><surname>Agosti</surname><given-names>C</given-names></name><name><surname>Costanzi</surname><given-names>C</given-names></name><name><surname>Archetti</surname><given-names>S</given-names></name><name><surname>Franzoni</surname><given-names>S</given-names></name><name><surname>Caltagirone</surname><given-names>C</given-names></name><name><surname>Di Luca</surname><given-names>M</given-names></name><name><surname>Caimi</surname><given-names>L</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name></person-group><article-title>Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT, 5-HTTLPR and APOE polymorphisms</article-title><source>Neurobiol. Aging</source><year>2006</year><volume>27</volume><issue>11</issue><fpage>1595</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">16257094</pub-id></element-citation></ref><ref id="R171"><label>171</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lanari</surname><given-names>A</given-names></name><name><surname>Amenta</surname><given-names>F</given-names></name><name><surname>Silvestrelli</surname><given-names>G</given-names></name><name><surname>Tomassoni</surname><given-names>D</given-names></name><name><surname>Parnetti</surname><given-names>L</given-names></name></person-group><article-title>Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease</article-title><source>Mech. Ageing Dev</source><year>2006</year><volume>127</volume><issue>2</issue><fpage>158</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">16297434</pub-id></element-citation></ref><ref id="R172"><label>172</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Alloza</surname><given-names>M</given-names></name><name><surname>Gil-Bea</surname><given-names>F J</given-names></name><name><surname>Diez-Ariza</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>C P</given-names></name><name><surname>Francis</surname><given-names>P T</given-names></name><name><surname>Lasheras</surname><given-names>B</given-names></name><name><surname>Ramirez</surname><given-names>M J</given-names></name></person-group><article-title>Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease</article-title><source>Neuropsychologia</source><year>2005</year><volume>43</volume><issue>3</issue><fpage>442</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15707619</pub-id></element-citation></ref><ref id="R173"><label>173</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>J L</given-names></name><name><surname>Kaufer</surname><given-names>D</given-names></name></person-group><article-title>Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited</article-title><source>Neurology</source><year>1996</year><volume>47</volume><issue>4</issue><fpage>876</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">8857712</pub-id></element-citation></ref><ref id="R174"><label>174</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lanctot</surname><given-names>K L</given-names></name><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Mazzotta</surname><given-names>P</given-names></name></person-group><article-title>Role of serotonin in the behavioral and psychological symptoms of dementia</article-title><source>J. Neuropsychiatry Clin. Neurosci</source><year>2001</year><volume>13</volume><issue>1</issue><fpage>5</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">11207325</pub-id></element-citation></ref><ref id="R175"><label>175</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Pritchard</surname><given-names>A L</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Pritchard</surname><given-names>C W</given-names></name><name><surname>Coates</surname><given-names>J</given-names></name><name><surname>Haque</surname><given-names>S</given-names></name><name><surname>Holder</surname><given-names>R</given-names></name><name><surname>Bentham</surname><given-names>P</given-names></name><name><surname>Lendon</surname><given-names>C L</given-names></name></person-group><article-title>Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease</article-title><source>Neurobiol. Aging</source><year>2008</year><volume>29</volume><issue>3</issue><fpage>341</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17098333</pub-id></element-citation></ref><ref id="R176"><label>176</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ueki</surname><given-names>A</given-names></name><name><surname>Ueno</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Shinjo</surname><given-names>H</given-names></name><name><surname>Morita</surname><given-names>Y</given-names></name></person-group><article-title>Serotonin transporter gene polymorphism and BPSD in mild Alzheimer's disease</article-title><source>J. Alzheimer's Dis</source><year>2007</year><volume>12</volume><issue>3</issue><fpage>245</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">18057558</pub-id></element-citation></ref><ref id="R177"><label>177</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Pritchard</surname><given-names>A L</given-names></name><name><surname>Pritchard</surname><given-names>C W</given-names></name><name><surname>Bentham</surname><given-names>P</given-names></name><name><surname>Lendon</surname><given-names>C L</given-names></name></person-group><article-title>Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients</article-title><source>Dement. Geriatr. Cogn. Disord</source><year>2007</year><volume>24</volume><issue>3</issue><fpage>201</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17690552</pub-id></element-citation></ref><ref id="R178"><label>178</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Proitsi</surname><given-names>P</given-names></name><name><surname>Lupton</surname><given-names>M K</given-names></name><name><surname>Reeves</surname><given-names>S J</given-names></name><name><surname>Hamilton</surname><given-names>G</given-names></name><name><surname>Archer</surname><given-names>N</given-names></name><name><surname>Martin</surname><given-names>B M</given-names></name><name><surname>Iyegbe</surname><given-names>C</given-names></name><name><surname>Hollingworth</surname><given-names>P</given-names></name><name><surname>Lawlor</surname><given-names>B</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Rubinsztein</surname><given-names>D C</given-names></name><name><surname>Owen</surname><given-names>M J</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Powell</surname><given-names>J F</given-names></name></person-group><article-title>Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia</article-title><source>Neurobiol. Aging</source><year>2012</year><volume>33</volume><issue>4</issue><fpage>791</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">20685009</pub-id></element-citation></ref><ref id="R179"><label>179</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>R A</given-names></name><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Lanctot</surname><given-names>K L</given-names></name></person-group><article-title>The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease</article-title><source>CNS Neurosci. Ther</source><year>2011</year><volume>17</volume><issue>5</issue><fpage>411</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">20560994</pub-id></element-citation></ref><ref id="R180"><label>180</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Meguro</surname><given-names>K</given-names></name><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Watanuki</surname><given-names>S</given-names></name><name><surname>Funaki</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Yamadori</surname><given-names>A</given-names></name><name><surname>Iwata</surname><given-names>R</given-names></name><name><surname>Itoh</surname><given-names>M</given-names></name></person-group><article-title>Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease</article-title><source>Ann. Nucl. Med</source><year>2003</year><volume>17</volume><issue>7</issue><fpage>567</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">14651356</pub-id></element-citation></ref><ref id="R181"><label>181</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Ueki</surname><given-names>A</given-names></name><name><surname>Ueno</surname><given-names>H</given-names></name><name><surname>Shinjo</surname><given-names>H</given-names></name><name><surname>Morita</surname><given-names>Y</given-names></name></person-group><article-title>Dopamine D3 receptor gene polymorphism influences on behavioral and psychological symptoms of dementia (BPSD) in mild dementia of Alzheimer's type</article-title><source>J. Alzheimer's Dis</source><year>2009</year><volume>17</volume><issue>2</issue><fpage>441</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19363270</pub-id></element-citation></ref><ref id="R182"><label>182</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Lanctot</surname><given-names>K L</given-names></name><name><surname>Khan</surname><given-names>L R</given-names></name></person-group><article-title>The role of norepinephrine in the behavioral and psychological symptoms of dementia</article-title><source>J. Neuropsychiatry Clin. Neurosci</source><year>2004</year><volume>16</volume><issue>3</issue><fpage>261</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">15377733</pub-id></element-citation></ref><ref id="R183"><label>183</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Alloza</surname><given-names>M</given-names></name><name><surname>Tsang</surname><given-names>S W</given-names></name><name><surname>Gil-Bea</surname><given-names>F J</given-names></name><name><surname>Francis</surname><given-names>P T</given-names></name><name><surname>Lai</surname><given-names>M K</given-names></name><name><surname>Marcos</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>C P</given-names></name><name><surname>Ramirez</surname><given-names>M J</given-names></name></person-group><article-title>Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease</article-title><source>Neurobiol. Aging</source><year>2006</year><volume>27</volume><issue>8</issue><fpage>1110</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15996794</pub-id></element-citation></ref><ref id="R184"><label>184</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lanctot</surname><given-names>K L</given-names></name><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Rothenburg</surname><given-names>L</given-names></name><name><surname>Eryavec</surname><given-names>G</given-names></name></person-group><article-title>Behavioral correlates of GABAergic disruption in Alzheimer's disease</article-title><source>Int. Psychogeriatr</source><year>2007</year><volume>19</volume><issue>1</issue><fpage>151</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16870038</pub-id></element-citation></ref><ref id="R185"><label>185</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>A</given-names></name><name><surname>Schubert</surname><given-names>K</given-names></name></person-group><article-title>Neurotransmitters regulating feline aggressive behavior</article-title><source>Rev. Neurosci</source><year>1995</year><volume>6</volume><issue>1</issue><fpage>47</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">7633640</pub-id></element-citation></ref><ref id="R186"><label>186</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Peeters</surname><given-names>B</given-names></name><name><surname>W</surname><given-names>Van Rijn</given-names></name><name><surname>C</surname><given-names>M</given-names></name><name><surname>Van Luijtelaar</surname><given-names>E L</given-names></name><name><surname>Coenen</surname><given-names>A M</given-names></name></person-group><article-title>Antiepileptic and behavioural actions of MK-801 in an animal model of spontaneous absence epilepsy</article-title><source>Epilepsy Res</source><year>1989</year><volume>3</volume><issue>2</issue><fpage>178</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">2495937</pub-id></element-citation></ref><ref id="R187"><label>187</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Wedzony</surname><given-names>K</given-names></name><name><surname>Fijal</surname><given-names>K</given-names></name><name><surname>Mackowiak</surname><given-names>M</given-names></name><name><surname>Chocyk</surname><given-names>A</given-names></name><name><surname>Zajaczkowski</surname><given-names>W</given-names></name></person-group><article-title>Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia</article-title><source>Neuroscience</source><year>2008</year><volume>153</volume><issue>4</issue><fpage>1370</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18434025</pub-id></element-citation></ref><ref id="R188"><label>188</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>P T</given-names></name></person-group><article-title>Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine</article-title><source>Curr. Mol. Pharmacol</source><year>2009</year><volume>2</volume><issue>1</issue><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">20021448</pub-id></element-citation></ref><ref id="R189"><label>189</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Noda</surname><given-names>Y</given-names></name><name><surname>Tsunekawa</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><name><surname>Senzaki</surname><given-names>K</given-names></name><name><surname>Nabeshima</surname><given-names>T</given-names></name></person-group><article-title>Behavioural and neurochemical features of olfactory bulbectomized rats resembling depression with comorbid anxiety</article-title><source>Behav. Brain Res</source><year>2007</year><volume>178</volume><issue>2</issue><fpage>262</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">17261334</pub-id></element-citation></ref><ref id="R190"><label>190</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Cryan</surname><given-names>J F</given-names></name><name><surname>O'Leary</surname><given-names>O F</given-names></name></person-group><article-title>Neuroscience. A glutamate pathway to
faster-acting antidepressants?</article-title><source>Science</source><year>2010</year><volume>329</volume><issue>5994</issue><fpage>913</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">20724626</pub-id></element-citation></ref><ref id="R191"><label>191</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>R J</given-names></name><name><surname>Banasr</surname><given-names>M</given-names></name><name><surname>Dwyer</surname><given-names>J M</given-names></name><name><surname>Iwata</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X Y</given-names></name><name><surname>Aghajanian</surname><given-names>G</given-names></name><name><surname>Duman</surname><given-names>R S</given-names></name></person-group><article-title>mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists</article-title><source>Science</source><year>2010</year><volume>329</volume><issue>5994</issue><fpage>959</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">20724638</pub-id></element-citation></ref><ref id="R192"><label>192</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Barkus</surname><given-names>C</given-names></name><name><surname>McHugh</surname><given-names>S B</given-names></name><name><surname>Sprengel</surname><given-names>R</given-names></name><name><surname>Seeburg</surname><given-names>P H</given-names></name><name><surname>Rawlins</surname><given-names>J N</given-names></name><name><surname>Bannerman</surname><given-names>D M</given-names></name></person-group><article-title>Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion</article-title><source>Eur. J. Pharmacol</source><year>2010</year><volume>626</volume><issue>1</issue><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">19836379</pub-id></element-citation></ref><ref id="R193"><label>193</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Labrie</surname><given-names>V</given-names></name><name><surname>Clapcote</surname><given-names>S J</given-names></name><name><surname>Roder</surname><given-names>J C</given-names></name></person-group><article-title>Mutant mice with reduced NMDA-NR1 glycine affinity or lack of D-amino acid oxidase function exhibit altered anxiety-like behaviors</article-title><source>Pharmacol. Biochem. Behav</source><year>2009</year><volume>91</volume><issue>4</issue><fpage>610</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">18940194</pub-id></element-citation></ref><ref id="R194"><label>194</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>R</given-names></name><name><surname>Ledgerwood</surname><given-names>L</given-names></name><name><surname>Cranney</surname><given-names>J</given-names></name></person-group><article-title>Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications</article-title><source>Learn. Mem</source><year>2004</year><volume>11</volume><issue>5</issue><fpage>510</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15466301</pub-id></element-citation></ref><ref id="R195"><label>195</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Bacanu</surname><given-names>S-A</given-names></name><name><surname>Devlin</surname><given-names>B</given-names></name><name><surname>Chowdari</surname><given-names>K V</given-names></name><name><surname>DeKosky</surname><given-names>S T</given-names></name><name><surname>Nimgaonkar</surname><given-names>V L</given-names></name><name><surname>Sweet</surname><given-names>R A</given-names></name></person-group><article-title>Linkage analysis of Alzheimer disease with psychosis</article-title><source>Neurology</source><year>2002</year><volume>59</volume><fpage>118</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12105318</pub-id></element-citation></ref><ref id="R196"><label>196</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ellison</surname><given-names>G</given-names></name></person-group><article-title>The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias</article-title><source>Brain Res. Brain Res. Rev</source><year>1995</year><volume>20</volume><issue>2</issue><fpage>250</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">7795658</pub-id></element-citation></ref><ref id="R197"><label>197</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Di Maria</surname><given-names>E</given-names></name><name><surname>Bonvicini</surname><given-names>C</given-names></name><name><surname>Bonomini</surname><given-names>C</given-names></name><name><surname>Alberici</surname><given-names>A</given-names></name><name><surname>Zanetti</surname><given-names>O</given-names></name><name><surname>Gennarelli</surname><given-names>M</given-names></name></person-group><article-title>Genetic variation in the G720/G30 gene locus (DAOA) influences the occurrence of psychotic symptoms in patients with Alzheimer's disease</article-title><source>J. Alzheimer's Dis</source><year>2009</year><volume>18</volume><issue>4</issue><fpage>953</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">20009237</pub-id></element-citation></ref><ref id="R198"><label>198</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Chumakov</surname><given-names>I</given-names></name><name><surname>Blumenfeld</surname><given-names>M</given-names></name><name><surname>Guerassimenko</surname><given-names>O</given-names></name><name><surname>Cavarec</surname><given-names>L</given-names></name><name><surname>Palicio</surname><given-names>M</given-names></name><name><surname>Abderrahim</surname><given-names>H</given-names></name><name><surname>Bougueleret</surname><given-names>L</given-names></name><name><surname>Barry</surname><given-names>C</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>La Rosa</surname><given-names>P</given-names></name><name><surname>Puech</surname><given-names>A</given-names></name><name><surname>Tahri</surname><given-names>N</given-names></name><name><surname>Cohen-Akenine</surname><given-names>A</given-names></name><name><surname>Delabrosse</surname><given-names>S</given-names></name><name><surname>Lissarrague</surname><given-names>S</given-names></name><name><surname>Picard</surname><given-names>F P</given-names></name><name><surname>Maurice</surname><given-names>K</given-names></name><name><surname>Essioux</surname><given-names>L</given-names></name><name><surname>Millasseau</surname><given-names>P</given-names></name><name><surname>Grel</surname><given-names>P</given-names></name><name><surname>Debailleul</surname><given-names>V</given-names></name><name><surname>Simon</surname><given-names>A M</given-names></name><name><surname>Caterina</surname><given-names>D</given-names></name><name><surname>Dufaure</surname><given-names>I</given-names></name><name><surname>Malekzadeh</surname><given-names>K</given-names></name><name><surname>Belova</surname><given-names>M</given-names></name><name><surname>Luan</surname><given-names>J J</given-names></name><name><surname>Bouillot</surname><given-names>M</given-names></name><name><surname>Sambucy</surname><given-names>J L</given-names></name><name><surname>Primas</surname><given-names>G</given-names></name><name><surname>Saumier</surname><given-names>M</given-names></name><name><surname>Boubkiri</surname><given-names>N</given-names></name><name><surname>Martin-Saumier</surname><given-names>S</given-names></name><name><surname>Nasroune</surname><given-names>M</given-names></name><name><surname>Peixoto</surname><given-names>H</given-names></name><name><surname>Delaye</surname><given-names>A</given-names></name><name><surname>Pinchot</surname><given-names>V</given-names></name><name><surname>Bastucci</surname><given-names>M</given-names></name><name><surname>Guillou</surname><given-names>S</given-names></name><name><surname>Chevillon</surname><given-names>M</given-names></name><name><surname>Sainz-Fuertes</surname><given-names>R</given-names></name><name><surname>Meguenni</surname><given-names>S</given-names></name><name><surname>Aurich-Costa</surname><given-names>J</given-names></name><name><surname>Cherif</surname><given-names>D</given-names></name><name><surname>Gimalac</surname><given-names>A</given-names></name><name><surname>Van Duijn</surname><given-names>C</given-names></name><name><surname>Gauvreau</surname><given-names>D</given-names></name><name><surname>Ouellette</surname><given-names>G</given-names></name><name><surname>Fortier</surname><given-names>I</given-names></name><name><surname>Raelson</surname><given-names>J</given-names></name><name><surname>Sherbatich</surname><given-names>T</given-names></name><name><surname>Riazanskaia</surname><given-names>N</given-names></name><name><surname>Rogaev</surname><given-names>E</given-names></name><name><surname>Raeymaekers</surname><given-names>P</given-names></name><name><surname>Aerssens</surname><given-names>J</given-names></name><name><surname>Konings</surname><given-names>F</given-names></name><name><surname>Luyten</surname><given-names>W</given-names></name><name><surname>Macciardi</surname><given-names>F</given-names></name><name><surname>Sham</surname><given-names>P C</given-names></name><name><surname>Straub</surname><given-names>R E</given-names></name><name><surname>Weinberger</surname><given-names>D R</given-names></name><name><surname>Cohen</surname><given-names>N</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name></person-group><article-title>Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia</article-title><source>Proc. Natl. Acad. Sci. U. S. A</source><year>2002</year><volume>99</volume><issue>21</issue><fpage>13675</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">12364586</pub-id></element-citation></ref><ref id="R199"><label>199</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y C</given-names></name><name><surname>Xi</surname><given-names>D</given-names></name><name><surname>Roman</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y Q</given-names></name><name><surname>Gao</surname><given-names>W J</given-names></name></person-group><article-title>Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex</article-title><source>J. Neurosci</source><year>2009</year><volume>29</volume><issue>49</issue><fpage>15551</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">20007479</pub-id></element-citation></ref><ref id="R200"><label>200</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>M H</given-names></name><name><surname>Chiu</surname><given-names>P H</given-names></name><name><surname>Lin</surname><given-names>C Y</given-names></name><name><surname>Chen</surname><given-names>H H</given-names></name></person-group><article-title>Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine</article-title><source>Schizophr. Res</source><year>2012</year><volume>136</volume><issue>1-3</issue><fpage>96</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">22325078</pub-id></element-citation></ref><ref id="R201"><label>201</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>S W</given-names></name><name><surname>Vinters</surname><given-names>H V</given-names></name><name><surname>Cummings</surname><given-names>J L</given-names></name><name><surname>Wong</surname><given-names>P T</given-names></name><name><surname>Chen</surname><given-names>C P</given-names></name><name><surname>Lai</surname><given-names>M K</given-names></name></person-group><article-title>Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease</article-title><source>Neurobiol. Aging</source><year>2008</year><volume>29</volume><issue>10</issue><fpage>1524</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">17433503</pub-id></element-citation></ref><ref id="R202"><label>202</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Tariot</surname><given-names>P N</given-names></name><name><surname>Farlow</surname><given-names>M R</given-names></name><name><surname>Grossberg</surname><given-names>G T</given-names></name><name><surname>Graham</surname><given-names>S M</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>Gergel</surname><given-names>I</given-names></name><name><surname>Group</surname><given-names>t M S</given-names></name></person-group><article-title>Memantine treatment in patients with moderate to severe alzheimer disease already receiving donepezil. A Randomized Controlled Trial</article-title><source>JAMA</source><year>2004</year><volume>291</volume></element-citation></ref><ref id="R203"><label>203</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>J L</given-names></name><name><surname>Schneider</surname><given-names>E</given-names></name><name><surname>Tariot</surname><given-names>P N</given-names></name><name><surname>Graham</surname><given-names>S M</given-names></name></person-group><article-title>Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment</article-title><source>Neurology</source><year>2006</year><volume>67</volume><issue>1</issue><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">16832078</pub-id></element-citation></ref><ref id="R204"><label>204</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>van Dyck</surname><given-names>C H</given-names></name><name><surname>Tariot</surname><given-names>P N</given-names></name><name><surname>Meyers</surname><given-names>B</given-names></name><name><surname>Malca</surname><given-names>R E</given-names></name></person-group><article-title>A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease</article-title><source>Alzheimer Dis. Assoc. Disord</source><year>2007</year><volume>21</volume><issue>2</issue><fpage>136</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">17545739</pub-id></element-citation></ref><ref id="R205"><label>205</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Cretu</surname><given-names>O</given-names></name><name><surname>Szalontay</surname><given-names>A S</given-names></name><name><surname>Chirita</surname><given-names>R</given-names></name><name><surname>Chirita</surname><given-names>V</given-names></name></person-group><article-title>Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil</article-title><source>Rev. Med. Chir. Soc. Med. Nat. Iasi</source><year>2008</year><volume>112</volume><issue>3</issue><fpage>641</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">20201245</pub-id></element-citation></ref><ref id="R206"><label>206</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Loft</surname><given-names>H</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name></person-group><article-title>Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis</article-title><source>Int. J. Geriatr. Psychiatry</source><year>2008</year><volume>23</volume><issue>5</issue><fpage>537</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">18058838</pub-id></element-citation></ref><ref id="R207"><label>207</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Wilcock</surname><given-names>G K</given-names></name><name><surname>Ballard</surname><given-names>C G</given-names></name><name><surname>Cooper</surname><given-names>J A</given-names></name><name><surname>Loft</surname><given-names>H</given-names></name></person-group><article-title>Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies</article-title><source>J. Clin. Psychiatry</source><year>2008</year><volume>69</volume><issue>3</issue><fpage>341</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18294023</pub-id></element-citation></ref><ref id="R208"><label>208</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Baumhackl</surname><given-names>U</given-names></name><name><surname>Berek</surname><given-names>K</given-names></name><name><surname>Brucke</surname><given-names>T</given-names></name><name><surname>Kapeller</surname><given-names>P</given-names></name><name><surname>Lechner</surname><given-names>A</given-names></name><name><surname>Rainer</surname><given-names>M</given-names></name><name><surname>Stogerer</surname><given-names>E M</given-names></name></person-group><article-title>[Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria]</article-title><source>Neuropsychiatrie : Klinik,
Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft
Osterreichischer Nervenarzte und Psychiater</source><year>2010</year><volume>24</volume><issue>2</issue><fpage>125</fpage><lpage>31</lpage></element-citation></ref><ref id="R209"><label>209</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Cappell</surname><given-names>J</given-names></name><name><surname>Eryavec</surname><given-names>G M</given-names></name><name><surname>Lanctot</surname><given-names>K L</given-names></name></person-group><article-title>Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study</article-title><source>CNS Drugs</source><year>2011</year><volume>25</volume><issue>5</issue><fpage>425</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">21476613</pub-id></element-citation></ref><ref id="R210"><label>210</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Clerici</surname><given-names>F</given-names></name><name><surname>Vanacore</surname><given-names>N</given-names></name><name><surname>Elia</surname><given-names>A</given-names></name><name><surname>Spila-Alegiani</surname><given-names>S</given-names></name><name><surname>Pomati</surname><given-names>S</given-names></name><name><surname>Da Cas</surname><given-names>R</given-names></name><name><surname>Raschetti</surname><given-names>R</given-names></name><name><surname>Mariani</surname><given-names>C</given-names></name></person-group><article-title>Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study</article-title><source>Neurolo Sci: Official Journal Ital Neurol Soc Ital Soc Clin Neurophysiol</source><year>2012</year><volume>33</volume><issue>1</issue><fpage>23</fpage><lpage>31</lpage></element-citation></ref><ref id="R211"><label>211</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>C</given-names></name><name><surname>Crugel</surname><given-names>M</given-names></name><name><surname>Maidment</surname><given-names>I</given-names></name><name><surname>Auestad</surname><given-names>B H</given-names></name><name><surname>Coulton</surname><given-names>S</given-names></name><name><surname>Treloar</surname><given-names>A</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Boustani</surname><given-names>M</given-names></name><name><surname>Katona</surname><given-names>C</given-names></name><name><surname>Livingston</surname><given-names>G</given-names></name></person-group><article-title>Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial</article-title><source>PloS One</source><year>2012</year><volume>7</volume><issue>5</issue><fpage>e35185</fpage><pub-id pub-id-type="pmid">22567095</pub-id></element-citation></ref><ref id="R212"><label>212</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Wirth</surname><given-names>Y</given-names></name><name><surname>Mobius</surname><given-names>H J</given-names></name></person-group><article-title>Effects of memantine 
on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies</article-title><source>Int. J. Geriatr. Psychiatry</source><year>2005</year><volume>20</volume><issue>5</issue><fpage>459</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">15852444</pub-id></element-citation></ref><ref id="R213"><label>213</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>G</given-names></name><name><surname>Lane</surname><given-names>H Y</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Chong</surname><given-names>M Y</given-names></name><name><surname>Lange</surname><given-names>N</given-names></name></person-group><article-title>Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia</article-title><source>Biol. Psychiatry</source><year>2004</year><volume>55</volume><issue>5</issue><fpage>452</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15023571</pub-id></element-citation></ref><ref id="R214"><label>214</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>H Y</given-names></name><name><surname>Chang</surname><given-names>Y C</given-names></name><name><surname>Liu</surname><given-names>Y C</given-names></name><name><surname>Chiu</surname><given-names>C C</given-names></name><name><surname>Tsai</surname><given-names>G E</given-names></name></person-group><article-title>Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study</article-title><source>Arch. Gen. Psychiatry</source><year>2005</year><volume>62</volume><issue>11</issue><fpage>1196</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">16275807</pub-id></element-citation></ref><ref id="R215"><label>215</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>H Y</given-names></name><name><surname>Huang</surname><given-names>C L</given-names></name><name><surname>Wu</surname><given-names>P L</given-names></name><name><surname>Liu</surname><given-names>Y C</given-names></name><name><surname>Chang</surname><given-names>Y C</given-names></name><name><surname>Lin</surname><given-names>P Y</given-names></name><name><surname>Chen</surname><given-names>P W</given-names></name><name><surname>Tsai</surname><given-names>G</given-names></name></person-group><article-title>Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia</article-title><source>Biol. Psychiatry</source><year>2006</year><volume>60</volume><issue>6</issue><fpage>645</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16780811</pub-id></element-citation></ref><ref id="R216"><label>216</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>H Y</given-names></name><name><surname>Liu</surname><given-names>Y C</given-names></name><name><surname>Huang</surname><given-names>C L</given-names></name><name><surname>Chang</surname><given-names>Y C</given-names></name><name><surname>Liau</surname><given-names>C H</given-names></name><name><surname>Perng</surname><given-names>C H</given-names></name><name><surname>Tsai</surname><given-names>G E</given-names></name></person-group><article-title>Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study</article-title><source>Biol. Psychiatry</source><year>2008</year><volume>63</volume><issue>1</issue><fpage>9</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17659263</pub-id></element-citation></ref><ref id="R217"><label>217</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>H Y</given-names></name><name><surname>Lin</surname><given-names>C H</given-names></name><name><surname>Huang</surname><given-names>Y J</given-names></name><name><surname>Liao</surname><given-names>C H</given-names></name><name><surname>Chang</surname><given-names>Y C</given-names></name><name><surname>Tsai</surname><given-names>G E</given-names></name></person-group><article-title>A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia</article-title><source>Int. J. Neuropsychopharmacol</source><year>2010</year><volume>13</volume><issue>4</issue><fpage>451</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">19887019</pub-id></element-citation></ref><ref id="R218"><label>218</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Heresco-Levy</surname><given-names>U</given-names></name><name><surname>Javitt</surname><given-names>D C</given-names></name><name><surname>Ermilov</surname><given-names>M</given-names></name><name><surname>Mordel</surname><given-names>C</given-names></name><name><surname>Silipo</surname><given-names>G</given-names></name><name><surname>Lichtenstein</surname><given-names>M</given-names></name></person-group><article-title>Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia</article-title><source>Arch. Gen. Psychiatry</source><year>1999</year><volume>56</volume><issue>1</issue><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">9892253</pub-id></element-citation></ref><ref id="R219"><label>219</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>D C</given-names></name><name><surname>Silipo</surname><given-names>G</given-names></name><name><surname>Cienfuegos</surname><given-names>A</given-names></name><name><surname>Shelley</surname><given-names>A M</given-names></name><name><surname>Bark</surname><given-names>N</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Lindenmayer</surname><given-names>J P</given-names></name><name><surname>Suckow</surname><given-names>R</given-names></name><name><surname>Zukin</surname><given-names>S R</given-names></name></person-group><article-title>Adjunctive high-dose glycine in the treatment of schizophrenia</article-title><source>Int. J. Neuropsychopharmacol</source><year>2001</year><volume>4</volume><issue>4</issue><fpage>385</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">11806864</pub-id></element-citation></ref><ref id="R220"><label>220</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Heresco-Levy</surname><given-names>U</given-names></name><name><surname>Javitt</surname><given-names>D C</given-names></name><name><surname>Ebstein</surname><given-names>R</given-names></name><name><surname>Vass</surname><given-names>A</given-names></name><name><surname>Lichtenberg</surname><given-names>P</given-names></name><name><surname>Bar</surname><given-names>G</given-names></name><name><surname>Catinari</surname><given-names>S</given-names></name><name><surname>Ermilov</surname><given-names>M</given-names></name></person-group><article-title>D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia</article-title><source>Biol. Psychiatry</source><year>2005</year><volume>57</volume><issue>6</issue><fpage>577</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">15780844</pub-id></element-citation></ref><ref id="R221"><label>221</label><element-citation publication-type="other" publisher-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C C</given-names></name><name><surname>Wei</surname><given-names>I H</given-names></name><name><surname>Huang</surname><given-names>C L</given-names></name><name><surname>Chen</surname><given-names>K T</given-names></name><name><surname>Tsai</surname><given-names>M H</given-names></name><name><surname>Tsai</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>K H</given-names></name><name><surname>Chang</surname><given-names>Y C</given-names></name><name><surname>Lane</surname><given-names>H Y</given-names></name><name><surname>Tsai</surname><given-names>G E</given-names></name></person-group><article-title>Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression</article-title><source>Biol Psychiatry, accepted</source></element-citation></ref><ref id="R222"><label>222</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Strick</surname><given-names>C A</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Scott</surname><given-names>L</given-names></name><name><surname>Harvey</surname><given-names>B</given-names></name><name><surname>Hajos</surname><given-names>M</given-names></name><name><surname>Steyn</surname><given-names>S J</given-names></name><name><surname>Piotrowski</surname><given-names>M A</given-names></name><name><surname>James</surname><given-names>L C</given-names></name><name><surname>Downs</surname><given-names>J T</given-names></name><name><surname>Rago</surname><given-names>B</given-names></name><name><surname>Becker</surname><given-names>S L</given-names></name><name><surname>El-Kattan</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ganong</surname><given-names>A H</given-names></name><name><surname>Tingley</surname><given-names>F D</given-names><suffix>3rd</suffix></name><name><surname>Ramirez</surname><given-names>A D</given-names></name><name><surname>Seymour</surname><given-names>P A</given-names></name><name><surname>Guanowsky</surname><given-names>V</given-names></name><name><surname>Majchrzak</surname><given-names>M J</given-names></name><name><surname>Fox</surname><given-names>C B</given-names></name><name><surname>Schmidt</surname><given-names>C J</given-names></name><name><surname>Duplantier</surname><given-names>A J</given-names></name></person-group><article-title>Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain</article-title><source>Neuropharmacology</source><year>2011</year><volume>61</volume><issue>5-6</issue><fpage>1001</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">21763704</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Behavioral Effect of AChE Inhibitors in Alzheimer&#x02019;s Disease</p></caption><table frame="border" rules="all"><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Design</th><th align="left" rowspan="1" colspan="1">Dosage
(per day)</th><th align="left" rowspan="1" colspan="1">Duration</th><th align="left" rowspan="1" colspan="1">Result</th></tr></thead><tbody><tr><td colspan="5" rowspan="1"><bold><italic>
Donepezil</italic></bold></td></tr><tr><td rowspan="1" colspan="1">Weiner, M.
F., <italic>et al</italic>. 2000 [<xref ref-type="bibr" rid="R148">148</xref>]</td><td rowspan="1" colspan="1">Open-label</td><td rowspan="1" colspan="1">5-10mg</td><td rowspan="1" colspan="1">48weeks</td><td rowspan="1" colspan="1">Significant
improvement in CBRSD<xref ref-type="table-fn" rid="T1F1">1</xref> total scores on Week 12. <break/>
Significant improvement in CBRSD depression and behavioral dysregulation
scores on Week 16. <break/>
CBRSD scores returned to baseline levels on Week 48</td></tr><tr><td rowspan="1" colspan="1">Gauthier, S.,
<italic>et al</italic>. 2002 [<xref ref-type="bibr" rid="R149">149</xref>]</td><td rowspan="1" colspan="1">Double-blind,
placebo-controlled </td><td rowspan="1" colspan="1">5-10mg</td><td rowspan="1" colspan="1">24weeks</td><td rowspan="1" colspan="1">Significant
improvement in following items of NPI<xref ref-type="table-fn" rid="T1F2">2</xref> scores:
depression/dysphoria, anxiety, and apathy/indifference.</td></tr><tr><td rowspan="1" colspan="1">Paleacu, D.,
<italic>et al</italic>. 2002 [<xref ref-type="bibr" rid="R150">150</xref>]</td><td rowspan="1" colspan="1">Open-label.</td><td rowspan="1" colspan="1">10 mg</td><td rowspan="1" colspan="1">24 weeks</td><td rowspan="1" colspan="1">Significant
improvement in NPI scores</td></tr><tr><td rowspan="1" colspan="1">Bergman, J.,
<italic>et al</italic>. 2003 [<xref ref-type="bibr" rid="R151">151</xref>]</td><td rowspan="1" colspan="1">Add-on
treatment.<break/>
Randomized, open-label.</td><td rowspan="1" colspan="1">5mg</td><td rowspan="1" colspan="1">4 weeks</td><td rowspan="1" colspan="1">Significant
improvement in PANSS<xref ref-type="table-fn" rid="T1F3">3</xref> scores. </td></tr><tr><td rowspan="1" colspan="1">Holmes, C.,
<italic>et al</italic>. 2004 [<xref ref-type="bibr" rid="R152">152</xref>]</td><td rowspan="1" colspan="1">Randomized
withdrawal</td><td rowspan="1" colspan="1">5-10mg</td><td rowspan="1" colspan="1">12 weeks</td><td rowspan="1" colspan="1">
Significant
improvement in NPI scores in group of continued donepezil treatment.</td></tr><tr><td rowspan="1" colspan="1">Cummings, J.
L., <break/>
<italic>et al</italic>. 2006 [<xref ref-type="bibr" rid="R153">153</xref>]</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5-10mg</td><td rowspan="1" colspan="1">20 weeks</td><td rowspan="1" colspan="1">No
significant change of NPI score on Week 8<break/>
Significant improvement in NPI scores on Week 20. </td></tr><tr><td rowspan="1" colspan="1">Howard, R.
J., <italic>et al</italic>. 2007 [<xref ref-type="bibr" rid="R154">154</xref>]</td><td rowspan="1" colspan="1">Randomized,<break/>
Double blind.</td><td rowspan="1" colspan="1">10mg</td><td rowspan="1" colspan="1">12 weeks</td><td rowspan="1" colspan="1">No
significant difference between donepezil and placebo in CMAI<xref ref-type="table-fn" rid="T1F4">4</xref>
scores and NPI scores.</td></tr><tr><td rowspan="1" colspan="1">Pelosi, A.
2008 [<xref ref-type="bibr" rid="R155">155</xref>]</td><td rowspan="1" colspan="1">Randomized,
double blind.</td><td rowspan="1" colspan="1">5-10mg</td><td rowspan="1" colspan="1">12 weeks</td><td rowspan="1" colspan="1">No
significant difference between donepezil and placebo in CMAI agitation
score and NPI scores.</td></tr><tr><td rowspan="1" colspan="1">Reekum, R.
2008 [<xref ref-type="bibr" rid="R156">156</xref>]</td><td rowspan="1" colspan="1">Randomized,
placebo-controlled </td><td rowspan="1" colspan="1">5-10mg</td><td rowspan="1" colspan="1">12 weeks</td><td rowspan="1" colspan="1">No
significant difference between donepezil and placebo in CMAI score </td></tr><tr><td rowspan="1" colspan="1">Carrasco, M.
M., <break/>
<italic>et al</italic>. 2011 [<xref ref-type="bibr" rid="R157">157</xref>]</td><td rowspan="1" colspan="1">Open-label,
noncomparative, prospective </td><td rowspan="1" colspan="1">5-10mg</td><td rowspan="1" colspan="1">24 weeks</td><td rowspan="1" colspan="1">Significant
improvement in NPI scores</td></tr><tr><td colspan="5" rowspan="1"><bold><italic>
Galantamine</italic></bold></td></tr><tr><td rowspan="1" colspan="1">Tariot, P.
N., <italic>et al</italic>. 2000 [<xref ref-type="bibr" rid="R158">158</xref>]</td><td rowspan="1" colspan="1">Double blind,
placebo controlled</td><td rowspan="1" colspan="1">8-24mg</td><td rowspan="1" colspan="1">20 weeks</td><td rowspan="1" colspan="1">Significant
improvement in NPI scores of galantamine 16- and 24-mg/day groups
compared to placebo.</td></tr><tr><td rowspan="1" colspan="1">Rockwood, K.,
<break/>
<italic>et al</italic>. 2001 [<xref ref-type="bibr" rid="R159">159</xref>]</td><td rowspan="1" colspan="1">Randomized,
double blind, placebo controlled</td><td rowspan="1" colspan="1">24-32mg</td><td rowspan="1" colspan="1">12 weeks</td><td rowspan="1" colspan="1">No
significant difference in NPI scores </td></tr><tr><td rowspan="1" colspan="1">Monsch, A. U.
and Giannakopoulos, P. 2004 [<xref ref-type="bibr" rid="R160">160</xref>]</td><td rowspan="1" colspan="1">Open-label.</td><td rowspan="1" colspan="1">8-24 mg</td><td rowspan="1" colspan="1">12 weeks</td><td rowspan="1" colspan="1">Significant
improvements in NPI scores. </td></tr><tr><td rowspan="1" colspan="1">Herrmann, N.,
<italic>et al</italic>. 2005 [<xref ref-type="bibr" rid="R161">161</xref>]</td><td rowspan="1" colspan="1">Post hoc
analysis of 3 randomized, double-blind, placebo-controlled trials.</td><td rowspan="1" colspan="1">16-32 mg</td><td rowspan="1" colspan="1">12-24 weeks</td><td rowspan="1" colspan="1">Significant
improvement in total NPI scores and individual domains of
agitation/aggression, anxiety, disinhibition, and aberrant motor
behavior</td></tr><tr><td colspan="5" rowspan="1"><bold><italic>
Rivastigmine</italic></bold></td></tr><tr><td rowspan="1" colspan="1">Finkel, S. I.
2004 [<xref ref-type="bibr" rid="R162">162</xref>]</td><td rowspan="1" colspan="1">Meta-analysis
of 3 randomized, placebo-controlled trials</td><td rowspan="1" colspan="1">6-12mg</td><td rowspan="1" colspan="1">24 weeks</td><td rowspan="1" colspan="1">Significant
improvement in the items of behavioral component of CIBIC-plus5:
paranoia, delusion, aggression, activity disturbance.</td></tr><tr><td rowspan="1" colspan="1">Cummings, J.
L., <break/>
<italic>et al</italic>. 2005 [<xref ref-type="bibr" rid="R163">163</xref>]</td><td rowspan="1" colspan="1">Prospective,
open-label.</td><td rowspan="1" colspan="1">3-12mg</td><td rowspan="1" colspan="1">26-week,</td><td rowspan="1" colspan="1">Decreased
NPI-NH<xref ref-type="table-fn" rid="T1F6">6</xref> score, but not statistically significant.<break/>
Significant improvement of follow the items of NPI-NH scores: delusions,
hallucinations, agitation, apathy/indifference, irritability/lability,
aberrant motor behavior, nighttime disturbances, and appetite/eating
changes</td></tr><tr><td rowspan="1" colspan="1">Edwards, K.,
<break/>
<italic>et al</italic>. 2005 [<xref ref-type="bibr" rid="R164">164</xref>]</td><td rowspan="1" colspan="1">Open label</td><td rowspan="1" colspan="1">3-12mg</td><td rowspan="1" colspan="1">52 weeks</td><td rowspan="1" colspan="1">Significant
improvements in following domains of NPI-NH: delusions, hallucinations,
anxiety and euphoria</td></tr><tr><td colspan="5" rowspan="1"><bold><italic>Rivastigmine</italic></bold></td></tr><tr><td rowspan="1" colspan="1">Gauthier, S.,<italic> et al</italic>.
2007 [<xref ref-type="bibr" rid="R165">165</xref>]</td><td rowspan="1" colspan="1">Open label.</td><td rowspan="1" colspan="1">3-12mg</td><td rowspan="1" colspan="1">24 weeks</td><td rowspan="1" colspan="1">At the end point, 62.3%,
62.6% and 56.0% patients had improvements in symptoms of anxiety, apathy
and agitation respectively.<break/>
However, 6.8%, 7.7% and 6.8% patients had worse symptoms of anxiety,
apathy and agitation respectively.</td></tr><tr><td colspan="5" rowspan="1"><bold><italic>Tarcrine</italic></bold></td></tr><tr><td rowspan="1" colspan="1">Kaufer, D. I., <italic>et al</italic>.
1996 [<xref ref-type="bibr" rid="R166">166</xref>]</td><td rowspan="1" colspan="1">Open label.</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Improvement of NPI scores</td></tr></tbody></table><table-wrap-foot><fn id="T1F1"><label>1</label><p>CBRSD: CERAD Behavior Rating Scale for Dementia.</p></fn><fn id="T1F2"><label>2</label><p>NPI: Neuropsychiatric Inventory</p></fn><fn id="T1F3"><label>3</label><p>PANSS; Positive and Negative Symptoms Scale</p></fn><fn id="T1F4"><label>4</label><p>CMAI: Cohen-Mansfield Agitation Inventory</p></fn><fn id="T1F5"><label>5</label><p>CIBIC-plus: Clinician's Interview-Based Impression of Change Plus Caregiver Input scale</p></fn><fn id="T1F6"><label>6</label><p>NPI-NH: Neuropsychiatric Inventory-Nursing Home</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Behavioral Effect of Memantine in Alzheimer&#x02019;s Disease</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Design</th><th align="left" rowspan="1" colspan="1">Dosage
(per day)</th><th align="left" rowspan="1" colspan="1">Duration</th><th align="left" rowspan="1" colspan="1"> Result</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Reisberg,
B.,<italic> et al</italic>. 2003 [<xref ref-type="bibr" rid="R201">201</xref>]</td><td rowspan="1" colspan="1">Randomized,
double blind, placebo controlled</td><td rowspan="1" colspan="1">20 mg</td><td rowspan="1" colspan="1">28weeks</td><td rowspan="1" colspan="1">No
significant difference between memantine and placebo in NPI scores</td></tr><tr><td rowspan="1" colspan="1">Tariot, P.
N., <italic>et al</italic>. 2004 [<xref ref-type="bibr" rid="R202">202</xref>]</td><td rowspan="1" colspan="1">Add-on
dopenezil treatment.<break/>
Randomized, placebo-controlled.</td><td rowspan="1" colspan="1">20 mg</td><td rowspan="1" colspan="1">24 weeks</td><td rowspan="1" colspan="1">Significant
improvement in NPI total scores</td></tr><tr><td rowspan="1" colspan="1">Cummings, J.
L., <break/>
<italic>et al</italic>. 2006 [<xref ref-type="bibr" rid="R203">203</xref>]</td><td rowspan="1" colspan="1">Add-on
dopenezil treatment.<break/>
Randomized, double-blind, placebo-controlled,</td><td rowspan="1" colspan="1">20mg</td><td rowspan="1" colspan="1">24 weeks</td><td rowspan="1" colspan="1">Significant
improvement over placebo in NPI<xref ref-type="table-fn" rid="T2F1">1</xref> total scores.</td></tr><tr><td rowspan="1" colspan="1">van Dyck, C.
H., <break/>
<italic>et al</italic>. 2007 [<xref ref-type="bibr" rid="R204">204</xref>]</td><td rowspan="1" colspan="1">Randomized,
double blind, placebo controlled</td><td rowspan="1" colspan="1">20 mg</td><td rowspan="1" colspan="1">24 weeks</td><td rowspan="1" colspan="1">No
significant difference between donepezil and placebo in NPI and BGP<xref ref-type="table-fn" rid="T2F2">2</xref>
scores</td></tr><tr><td rowspan="1" colspan="1">Cretu, O.,
<italic>et al</italic>. 2008 [<xref ref-type="bibr" rid="R205">205</xref>]</td><td rowspan="1" colspan="1">Add-on
dopenezil treatment.<break/>
Randomized</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">24 weeks</td><td rowspan="1" colspan="1">Significant
improvement in agitation/aggression compared with donepezil monotherapy</td></tr><tr><td rowspan="1" colspan="1">Gauthier,
S., <italic>et al</italic>. 2008 [<xref ref-type="bibr" rid="R206">206</xref>]</td><td rowspan="1" colspan="1">Pooled
analysis of 6 randomized, double blind, placebo controlled trials.</td><td rowspan="1" colspan="1">20mg</td><td rowspan="1" colspan="1">24 or 28
weeks</td><td rowspan="1" colspan="1">Significant
improvement in NPI total scores and the items: delusions,
hallucinations, agitation/aggression and irritability/lability</td></tr><tr><td rowspan="1" colspan="1">Wilcock, G.
N., <break/>
<italic>et al</italic>. 2008 [<xref ref-type="bibr" rid="R207">207</xref>]</td><td rowspan="1" colspan="1">Pooled
analysis of 3 randomized trials</td><td rowspan="1" colspan="1">20mg</td><td rowspan="1" colspan="1">24 or 28
weeks</td><td rowspan="1" colspan="1">Significant
advantage in following domains of NPI: agitation/aggression, delusion,
hallucination.</td></tr><tr><td rowspan="1" colspan="1">Schmidt, R.,
<italic>et al</italic>. 2010 [<xref ref-type="bibr" rid="R208">208</xref>]</td><td rowspan="1" colspan="1">Naturalistic
study</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">16 weeks</td><td rowspan="1" colspan="1">Improvement in NPI total scores. </td></tr><tr><td rowspan="1" colspan="1">Herrmann,
N., <italic>et al</italic>. 2011 [<xref ref-type="bibr" rid="R209">209</xref>]</td><td rowspan="1" colspan="1">Open-label</td><td rowspan="1" colspan="1">20mg</td><td rowspan="1" colspan="1">12 weeks</td><td rowspan="1" colspan="1">Significant improvement in agitation/aggression domains of NPI-NH<xref ref-type="table-fn" rid="T2F3">3</xref>.</td></tr><tr><td rowspan="1" colspan="1">Clerici, F.,
<italic>et al</italic>. 2012 [<xref ref-type="bibr" rid="R210">210</xref>]</td><td rowspan="1" colspan="1">
Post-marketing surveillance study</td><td rowspan="1" colspan="1">20mg</td><td rowspan="1" colspan="1">6 months</td><td rowspan="1" colspan="1">Significant
behavioral improvement in patients who taking 20 mg memantine daily.</td></tr><tr><td rowspan="1" colspan="1">Fox, C.,<italic>
et al</italic>. 2012 [<xref ref-type="bibr" rid="R211">211</xref>]</td><td rowspan="1" colspan="1">Randomized,
double blind, placebo controlled</td><td rowspan="1" colspan="1">20mg</td><td rowspan="1" colspan="1">12 weeks</td><td rowspan="1" colspan="1">No
significant difference between memantine and placebo in CMAI<xref ref-type="table-fn" rid="T2F4">4</xref>
<break/>
Significant improvement over placebo in NPI total scores.</td></tr></tbody></table><table-wrap-foot><fn id="T2F1"><label>1</label><p>NPI: Neuropsychiatric Inventory.</p></fn><fn id="T2F2"><label>2</label><p>BGP: Behavioral rating scale for geriatric patients.</p></fn><fn id="T2F3"><label>3</label><p>NPI-NH: Neuropsychiatric Inventory-Nursing Home</p></fn><fn id="T2F4"><label>4</label><p>CMAI: Cohen-Mansfield Agitation Inventory</p></fn></table-wrap-foot></table-wrap></floats-group></article>